



HAL
open science

MUB40 Binds to Lactoferrin and Stands as a Specific Neutrophil Marker

Mark C. Anderson, Thibault Chaze, Yves-Marie Coïc, Louise Injarabian, Friederike Jönsson, Naelle Lombion, Dorothée Selimoglu-Buet, Judith Souphron, Caroline Ridley, Pascale Vonaesch, et al.

► **To cite this version:**

Mark C. Anderson, Thibault Chaze, Yves-Marie Coïc, Louise Injarabian, Friederike Jönsson, et al.. MUB40 Binds to Lactoferrin and Stands as a Specific Neutrophil Marker. *Cell Chemical Biology*, 2018, 25 (4), pp.483-493.e9. 10.1016/j.chembiol.2018.01.014 . pasteur-02573125

HAL Id: pasteur-02573125

<https://pasteur.hal.science/pasteur-02573125>

Submitted on 5 Feb 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License



MUB₄₀ Binds to Lactoferrin and Stands as a Specific Neutrophil Marker

DOI:

[10.1016/j.chembiol.2018.01.014](https://doi.org/10.1016/j.chembiol.2018.01.014)

Document Version

Accepted author manuscript

[Link to publication record in Manchester Research Explorer](#)

Citation for published version (APA):

Anderson, M. C., Chaze, T., Coïc, Y. M., Injarabian, L., Jonsson, F., Lombion, N., Selimoglu-Buet, D., Souphron, J., Ridley, C., Vonaesch, P., Baron, B., Arena, E. T., Tinevez, J. Y., Nigro, G., Nothelfer, K., Solary, E., Lapierre, V., Lazure, T., Matondo, M., ... Marteyn, B. S. (2018). MUB₄₀ Binds to Lactoferrin and Stands as a Specific Neutrophil Marker. *Cell Chemical Biology*, 25(4), 483-493.e9. <https://doi.org/10.1016/j.chembiol.2018.01.014>

Published in:

Cell Chemical Biology

Citing this paper

Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights

Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy

If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [<http://man.ac.uk/04Y6Bo>] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.



Cell Chemical Biology

MUB40 binds to lactoferrin and stands as a specific neutrophil marker

--Manuscript Draft--

Manuscript Number:	CELL-CHEMICAL-BIOLOGY-D-17-00386R1
Full Title:	MUB40 binds to lactoferrin and stands as a specific neutrophil marker
Article Type:	Research Article
Keywords:	neutrophil; biomarker; lactoferrin; imaging
Corresponding Author:	Benoit S Marteyn, PhD Institut Pasteur Paris, Île-de-France FRANCE
First Author:	Anderson Mark, PhD
Order of Authors:	Anderson Mark, PhD Thibault Chaze, PhD Yves-Marie Coic, technician Louise Injarabian, Master Friederike Jonsson, PhD Naelle Lombion, MD Dorothee Selimoglu Buet, PhD Judith Souphron, PhD Caroline Ridley, PhD Pascale Vonaesch, PhD Bruno Baron, technician Ellen T Arena, PhD Jean-Yves Tinevez, PhD Giulia Nigro, PhD Katarina Nothelfer, PhD Eric Solary, MD, PhD Valérie Lapierre, MD, PhD Thierry Lazure, MD, PhD Marianne Matondo, PhD David Thornton, PhD Philippe J Sansonetti, MD, PhD Françoise Baleux, PhD Benoit S Marteyn, PhD
Abstract:	Neutrophils are the most abundant immune cells recruited to inflamed tissues. Due to the lack of dedicated tools, their detection and study has been hampered. Here, we show that MUB40, binds to lactoferrin, the most abundant protein stored in neutrophil specific and tertiary. Lactoferrin is specifically expressed and secreted by neutrophils among other leucocytes, making MUB40 a specific neutrophil marker. Naïve mammal neutrophils were efficiently labelled with fluorescent MUB40-conjugates (-Cy5, Dylight405). A peptidase-resistant retro-inverso MUB40 peptide (RI-MUB40) was synthesized and its lactoferrin-binding property was validated. Neutrophil lactoferrin secretion was assessed in vitro by live microscopy on infected neutrophils in the presence of RI-MUB40-Cy5. Systemically administered RI-MUB40-Cy5 accumulated at

	<p>sites of inflammation in vivo in a mouse arthritis model and therefore proposes itself as a potential novel tool. Improving neutrophils' detection with the universal and specific MUB40 marker will promote their study in inflammatory diseases.</p>
Suggested Reviewers:	<p>Agneta Richter-Dahlfors, PhD Professor, Karolinska Institutet, Sweden Agneta.Richter.Dahlfors@ki.se Expert in infection/inflammation imaging techniques and biomarker development</p>
	<p>Charaf Benarafa, PhD Professor, University of Bern, Switzerland charaf.benarafa@tki.unibe.ch Expert in neutrophil biology and imaging techniques</p>
	<p>Jonathan Jantsch, MD, PhD Professor, University of Regensburg, Germany Jonathan.Jantsch@klinik.uni-regensburg.de Expert in animal models of bacterial infection/Innate immune response</p>
	<p>Edwin R Chilvers, MD, PhD Professor, University of Cambridge, UK erc24@cam.ac.uk Expert in neutrophil physiology, animal models of inflammation, clinical trials</p>
Opposed Reviewers:	



Paris, le 04/12/17

Unité de Pathogénie
Microbienne Moléculaire
INSERM U786
Institut Pasteur
28 rue du Dr Roux
F - 75724 PARIS Cédex 15
France

De : *Dr. Benoit Marteyn*

Téléphone: (33-0) 1 45 68 38 94

Télécopie: (33-0) 1 45 68 89 53

E-mail: marteyn@pasteur.fr

OBJET: Revised version manuscript CELL-CHEMICAL-BIOLOGY-D-17-00386.

Dear Dr. Ciancetta,

We thank you for the opportunity to resubmit a revised version of our manuscript entitled: «The MUB₄₀ peptide binds to lactoferrin and stands as a specific neutrophil marker» by Anderson and colleagues. We have addressed all the reviewer comments and critics and we performed requested experiments.

We have included additional results in this new version of our manuscript (mainly Figures 2, 3 and S2). Importantly, based on a reviewer comment, we have now demonstrated that MUB40 can be used as a neutrophil marker using flow cytometry. We thank the reviewer suggestion.

We are looking forward to hearing from you, do not hesitate to contact me for further missing informations.

Sincerely,

Benoit Marteyn, PhD
Senior scientist, CR1 Inserm (U1202)
Institut Pasteur, Paris - Unité de Pathogénie Microbienne Moléculaire
Gustave Roussy Cancer Campus, Villejuif – Laboratoire de Thérapie Cellulaire
France

REVIEWERS' COMMENTS

We thank the reviewers for their time and thoughtful comments. Please find below our answers and additions.

Reviewer #1: The authors provide evidence that MUB40 allows for reliable detection of lactoferrin and thereby might serve as strategy to visualize neutrophils in vivo. The authors describe the chemical synthesis, structure and binding properties of MUB40 and a retro-inverso peptidase resistant version of MUB40. They move on and demonstrate that MUB40 labels human and other mammalian granulocytes. They provide evidence that lactoferrin is stored in specific and tertiary granules. Of utmost interest they demonstrate that their strategy allows for detection of lactoferrin degranulation in vitro using live cell imaging by using a peptidase-resistant retro-inverso MUB40 peptide.

This is an exciting report on a new strategy to assess inflammation by using a specific ligand for an antimicrobial molecules. This strategy might pave the way to new tools for visualization of inflammatory processes in general and therefore is of broad interest.

My only concern is related to the issue whether lactoferrin is granulocyte specific. I acknowledge that the authors tested whether Lactoferrin is expressed in CD14+ human monocytes, Cd19+ B cells and CD3+ T cells. However, according to Immgen database (<https://www.immgen.org/>) lactoferrin (lactotransferrin, Ltf) is expressed in BM-macrophages, Ly6C+ classical monocytes; some expression also in B cell precursors and hematopoietic stem cells in the mouse (Immgen database; [immgen.org](https://www.immgen.org/)). Since the authors claim that Lactoferrin might serve as a marker for granulocytes I feel that a analysis of these cell types is warranted as well (e.g. isolation of the cells ex vivo (e.g. by FACS sorting) and staining with the retro-inverso MUB40 as done in Fig. 5.)

We thank the reviewer for this comment and we agree that the potential use of MUB40 in flow cytometry was not described in our original manuscript. In the revised version, we included new results showing that in human and mouse blood samples, neutrophils are specifically labeled with MUB40 fluorescent conjugates. None of the other mature leucocytes (including Ly6C+ classical monocytes) are labeled with these markers. Since we previously demonstrated that human CD34+ HSC were not labeled with MUB40 fluorescent conjugates (Figure 2B), we confirm here the specificity of the neutrophil labeling (page 9, lines 7-18). To our knowledge, lactoferrin is only detected at high concentrations in neutrophil granules and in secreted fluids (including milk). In the Immgen database mentioned by the reviewer, we did not find any original manuscript describing the expression of lactoferrin in monocytes.

Minor:

- Labelling of Fig. 4 C. What does "FT" stand for?

FT corresponds to the flow-through fraction (unbound). This comment has been included in the revised figure legend (page 30)

line 3)

- The authors might want to consider elaborating in more detail on the synthesis of the MUB40 and retro-inverso peptide.

We thank the reviewer for noticing these missing information which have not been included, by mistake, in the submitted manuscript. We re-introduced this section in the supplementary informations (from page 2 line 1 to page 3 line 8) and referred in the main text (page 6 line 3).

Reviewer #2:

This paper outlines an impressive piece of work in which the authors synthesize and validate a new neutrophil marker using an extensive range on in vivo and in vitro models.

The paper appears technically sound, with each experiment well reasoned and explained. The paper displays a logical progression from synthesis through the various complexities of models. The authors outline potential follow-up studies and for the most-part the information given would allow re-use.

We thank the reviewer for these positive and encouraging statements.

Below I have outlined my few points that could benefit from further explanation:

1. Differentiation between Mub40 and Mub70. In the discussion the authors note that both MUB70 and Mub40 labeled neutrophil granules by interacting with a lactoferrin glycosylation moiety. What therefore is the advantage of Mub40 over Mub70?

The main advantages of MUB40 compared to MUB70 are associated to its shorter length making its synthesis quicker, easier and cost-effective. It allowed the design and production of various forms of MUB40 with different conjugated molecules (various fluorophores, biotin, etc..) and a non-cleavable retro-inverso version.

The lonely functional difference between MUB40 and MUB70 is its ability to label goblet cell granules, probably due to its smaller size (Figure 1B and main text, page 6 lines 6-9).

2. Could the authors further define the transient nature of the Mub40 labeling in live cells? What is the concentration co-efficient of the labeling vs lactoferrin concentration? It appears the transient nature is more pronounced in cell culture than in vivo.

We thank the reviewer for raising this important question. Unfortunately, the lactoferrin concentration in neutrophil granules vs supernatant is difficult to assess. MUB40 concentration in labeling solution is high enough to allow the detection of high lactoferrin concentration in animal/human inflammatory sites (Fig. 5B/C and Fig. 6)

The transient RIMUB40 labeling of neutrophils infected with

Shigella has not yet been minded. As we can rule out the possibility of RIMUB40 degradation, we think that it may be due to the solubilization of secreted lactoferrin in the culture medium. Although labeled with RIMUB40, the resulting fluorescent signal might not be high enough to be detected with a fluorescent microscope. Conversely, at the site of degranulation on the cell surface lactoferrin is more concentrated and detected with RIMUB40 (main text, page 10 lines 22-24). In vivo, we hypothesize that lactoferrin may be accumulating within inflammatory foci, (figs. 5B and 5C) (main text page 11 line 5 and page 11 lines 16-20). This point was further outlined in page 6 line 18 «(inflammatory sites) are hypothesized to contain a high concentrated level of lactoferrin »

3. If both Mub40 and Mub70 label colonic mucosa, why is there no apparent labeling on the colonic mucosa in Figure 3c? Is the Mub40 signal in 3C only extracellular?

We acknowledge that the mouse colonic mucus is not labeled with MUB40 in Fig. 3C, which is consistent with the inefficient labeling of mouse colonic mucus with MUB70, compared to human, guinea pig, rabbit colonic mucus, as described in Coic et al, 2012, J. Biol. Chem. This observation remains unexplained.

4. Is any specific permeation step needed to enable MuB40 labeling in fixed cells?

After fixation, neutrophils are labeled with MUB40 in the presence of a detergent, either Saponin (0.1%) or Triton (0.1%). The potential use of Triton has been further outlined in the revised version of the manuscript (main text p20, line 1)

5. How many mice were included in each of the 2 experiments in the 5C? Can the authors comment on the apparent fluorescent signal from the animals spine?

In the experiment shown in 5C I originally started with 5 ctrl mice + 5 arthritic mice, however 1 of the arthritic mice died during the imaging preparation, so in this group are only 4 mice (as indicated in the Figure Legend) which results in 10 and 8 imaged hind ankles.

In the first experiment, we included 3 ctrl and 5 arthritic mice - but I recall that the imaging settings were quite different... Finally, in the latest experiment we have 4 controls and 5 K/BxN mice (which is probably the better repetition in the end than the first one).

The signal that appears to result from the spinal cord is in fact due to a superficial injury of the skin that occurred during the shaving/depilation of the animal. Superficial signals appear indeed very strong with this imaging technique as they are not quenched by their passage through tissues as the ones from the

ankle joints. As a consequence, small skin lesions due to injury or mouse bites appear indeed very strong.

MUB₄₀ binds to I□□□□□□□□□□ and stands as a specific neutrophil marker

1
2
3
4
5
6 Mark Anderson^{1,2,€}, Thibault Chaze^{3,€}, Yves-Marie Coïc^{4,€}, Louise Injarabian^{1,2,5},
7
8 Friederike Jonsson^{6,7}, Naelle Lombion⁸, Dorothée Selimoglu-Buet⁹, Judith
9
10 Souphron^{1,2}, Caroline Ridley¹⁰, Pascale Vonaesh^{1,2}, Bruno Baron¹¹, Ellen T
11
12 Arena^{1,2,£}, Jean-Yves Tinevez¹², Giulia Nigro^{1,2}, Katharina Nothelfer^{1,2}, Eric Solary⁹,
13
14 Valérie Lapierre⁸, Thierry Lazure¹³, Mariette Matondo³, David Thornton⁶, Philippe
15
16 Sansonetti^{1,2,14}, Françoise Baleux⁴, Benoit S Marteyn^{1,2,8 *}
17
18
19
20
21
22
23
24

25 ¹Institut Pasteur, Unité de Pathogénie Microbienne Moléculaire, 28 rue du Dr Roux,
26
27 75724 Paris Cedex 15, France
28
29
30

31 ²INSERM Unité 1202, 28 rue du Dr Roux, 75724 Paris Cedex 15, France
32
33

34 ³Institut Pasteur / CNRS USR 2000 Mass Spectrometry for Biology, Proteomics
35
36 Platform, CITECH, 28 rue du Dr Roux, 75724 Paris Cedex 15, France
37
38
39

40 ⁴Institut Pasteur, Unité de Chimie des Biomolécules, CNRS UMR 3523, 28 rue du Dr
41
42 Roux, 75724 Paris Cedex 15, France
43
44

45 ⁵CNRS, IBGC, Cell Energetic Metabolism, 1, rue Camille Saint Saëns CS 61390
46
47 33077 Bordeaux cedex
48
49
50

51 ⁶Institut Pasteur, Département d'Immunologie, 25 rue du Docteur Roux, 75024 Paris
52
53 Cedex 15, France
54
55
56

57 ⁷INSERM Unité 1222, 25 rue du Dr Roux, 75015 Paris Cedex 15, France
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

⁸Institut Gustave Roussy, Laboratoire de Thérapie Cellulaire, 114 Rue Edouard Vaillant, 94800 Villejuif, France

⁹Institut Gustave Roussy Inserm U1009, 114 Rue Edouard Vaillant, 94800 Villejuif, France

¹⁰University of Manchester, Wellcome Trust Centre for Cell-Matrix Research, Faculty of Biology, Medicine and Health, A V Hill Building, Manchester M13 9PT, UK

¹¹Institut Pasteur, Plate-Forme de Biophysique Moléculaire, 28 rue du Dr Roux, 75724 Paris Cedex 15, France

¹²Institut Pasteur, CITECH, Imagopole, 28 rue du Dr Roux, 75724 Paris Cedex 15, France

¹³APHP Hopital du Kremlin-Bicêtre, 78 Rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France

¹⁴Collège de France, Paris, France

€ These authors contributed equally to this work

£ present address : Morgridge Institute for Research / LOCI, 330 N Orchard St., Madison, WI 53715, USA

* Corresponding author: Benoit Marteyn (marteyn@pasteur.fr), Institut Pasteur, Unité PMM, 28, rue du Dr. Roux 75724 Paris Cedex 15, France; Phone +33 1 45488308; Fax +33 1 45488953

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

1
2
3 Neutrophils are the most abundant immune cells recruited to inflamed tissues.
4
5 Due to the lack of dedicated tools, their detection and study has been
6
7 hampered. Here, we show that MUB₄₀, binds to lactoferrin, the most abundant
8
9 protein stored in neutrophil specific and tertiary. Lactoferrin is specifically
10
11 expressed and secreted by neutrophils among other leucocytes, making
12
13 MUB₄₀ a specific neutrophil marker. Naïve mammal neutrophils were efficiently
14
15 labelled with fluorescent MUB₄₀-conjugates (-Cy5, Dylight405). A peptidase-
16
17 resistant retro-inverso MUB₄₀ peptide (RI-MUB₄₀) was synthesized and its
18
19 lactoferrin-binding property was validated. Neutrophil lactoferrin secretion was
20
21 assessed *in vitro* by live microscopy on infected neutrophils in the presence of
22
23 RI-MUB₄₀-Cy5. Systemically administered RI-MUB₄₀-Cy5 accumulated at sites
24
25 of inflammation *in vivo* in a mouse arthritis model and therefore proposes
26
27 itself as a potential novel tool. Improving neutrophils' detection with the
28
29 universal and specific MUB₄₀ marker will promote their study in inflammatory
30
31 diseases.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Introduction

Polymorphonuclear neutrophils are the most abundant immune cell population recruited to inflammatory tissues. Once recruited, neutrophils release proteins and cytokines contributing to the overall innate immune response. Proteins secreted by neutrophils upon their stimulation, are stored in pre-formed granules. Neutrophils contain four distinct granule populations named azurophil granules (α), specific granules (β 1), tertiary granules (β 2) and secretory vesicles (γ), which are sequentially formed during granulopoiesis. When activated, neutrophils sequentially release the protein content of stored granules. Granules formed during the later stage of granulopoiesis are more prone to exocytosis. Neutrophil granule protein content has been first investigated by Borregaard and colleagues and since then extensively studied *in vitro* and *in vivo* during inflammation and immune response (Cowland and Borregaard, 2016; Kjeldsen et al., 1999; Sengelov et al., 1995) (Borregaard et al., 2007) (Faurischou and Borregaard, 2003) (Soehnlein et al., 2009). Increased seric concentrations of neutrophil secreted proteins were reported in various inflammatory diseases such as inflammatory bowel disease (IBD) (Gouni-Berthold et al., 1999) or colorectal cancer (Ho et al., 2014). Inflammatory states were also correlated with high concentration of neutrophil secreted proteins in faeces (IBD (Däbritz et al., 2014) (Lehmann et al., 2015)) or in sputum (cystic fibrosis (Sagel et al., 2012)).

Among neutrophil secreted proteins, lactoferrin is the most abundant and suitable neutrophil-derived faecal marker of inflammation (Sugi et al., 1996) (Martins et al., 1995) including IBD (Sipponen, 2013) (Stragier and Van Assche, 2013). However, to date, no inflammation-imaging method based on lactoferrin detection is described, although specifically stored in neutrophil granules, and not expressed by other white

1 blood cells. Lactoferrin is an 80 kDa glycoprotein produced by neutrophils and
2 exocrine glands located in respiratory and gastrointestinal tracts (Peen et al., 1996).
3
4 Lactoferrin antimicrobial activity is associated with its iron sequestration property,
5 limiting pathogens' (bacteria, viruses, fungi) survival and spreading (Orsi, 2004).
6
7 Neutrophil lactoferrin is locally secreted by neutrophils at bacterial infection sites
8
9 (Masson et al., 1969).
10
11
12
13
14

15 Here we characterize MUB₄₀, a novel marker of neutrophils, which binds to
16 neutrophil lactoferrin, stored in β 1 or β 2 granules and released in the extracellular
17 compartment, upon neutrophil activation. Here, MUB₄₀ has been validated as a new
18 inflammation marker in an infectious inflammatory model in tissues infected with the
19 pathogenic enterobacteria *Shigella flexneri*, but also in sterile inflammatory models.
20
21
22
23
24
25
26
27
28
29
30

31 **Results**

32 **MUB₄₀-peptides chemical synthesis, structure, and binding properties**

33
34
35
36
37
38
39 MUB₄₀ is a 40-amino acid peptide, derived from the MUB₇₀ marker, originally
40 characterized for its ability to bind the human colonic mucus (Coïc et al., 2012). Four
41 overlapping 40-amino acid peptides (named MUB₄₀#1, MUB₄₀#2, MUB₄₀#3, and
42 MUB₄₀#4) covering the MUB₇₀ sequence were designed (Figure 1A), chemically
43 synthesized (see Methods), and conjugated to fluorophore or biotin via the N-ter
44 added cysteine when required for further study (see Supplementary Methods). The
45 MUB₄₀ peptide synthesis strategy was set up based on MUB₇₀ synthesis (Coïc et al.,
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 dipeptides (Figure S1A). As a result, lowering of aggregation propensity and
2 aspartimide formation produced the MUB₄₀ peptide with a satisfactory yield (see
3 Supplemental Methods for detailed information).
4
5

6
7
8 MUB₄₀#1 (corresponding to MUB₇₀ C-terminal part), conjugated to Cy5 (MUB₄₀#1-
9 Cy5) was the only peptide, which conserved the ability to bind to and fluorescently
10 label the human colonic mucus (Figure 1B and S1B). In contrast with MUB₇₀-Cy5,
11 MUB₄₀#1-Cy5 allowed in addition the labelling of goblet cell granules on fixed slides,
12 most likely due to its reduced size and the resulting improved accessibility to granule
13 content (Figure 1C). Similarly to MUB₇₀ (Coïc et al., 2012), we show here by
14 Analytical Gel Filtration (see Supplemental Methods) that MUB₄₀#1 (theoretical MW
15 4.9 kDa), combined as a trimer (experimental Mr 15.9 kDa), unlike the three others
16 overlapping peptides which rather organized as tetramers (MUB₄₀#2 theo MW 4.8
17 kDa; exp: Mr 22.0 kDa, MUB₄₀#3 theo MW 4.9 kDa; exp Mr 20.5, and MUB₄₀#4 theo
18 MW 4.8 kDa; exp Mr 20,4 kDa) (Figure 1D). The structure of MUB₄₀ peptides was
19 analyzed by Circular Dichroism (CD). The four resulting signals were almost similarly
20 shaped and could be assigned to unstructured peptide chains or polyproline II-like
21 scaffolds (Fig 1E). In regards to the thermal transition curves (data not shown), no
22 obvious conformational changes were identified and we assumed a global unordered
23 structure for all peptides. Nevertheless, slight differences were observed between
24 the CD spectra, mostly in the negative band within the 200 nm range: MUB₄₀#1
25 showed a lower intensity signal, significantly 1 to 1,5 nm red-shifted, as compared to
26 other MUB₄₀ peptides (#2, #3 and #4) minima. Even if no structural element was
27 evidenced from the CD profiles, this singularity could reflect a specific feature of
28 MUB₄₀#1. As a conclusion, MUB₄₀#1, hereafter-named MUB₄₀, highlighted a similar
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 oligomerization state and mucus-binding properties compared to MUB₇₀ and was
2 further characterized in this study.
3
4
5
6
7

8 **MUB₄₀ labels human and other mammalian granulocytes**

9
10
11 In addition to its colonic mucus binding property, confirmed on fixed human colon
12 explants infected with *Shigella flexneri* (*S. flexneri*) (Figure 1F, see Methods),
13 MUB₄₀-Cy5 labelled a specific cell population in the colonic mucosa, which were
14 hypothesized to be polymorphonuclear neutrophils (neutrophils), the most abundant
15 immune cell population recruited upon *Shigella* invasion (Sansonetti et al., 1999). To
16 confirm this hypothesis, human neutrophils were purified from healthy volunteers
17 (see Supplementary Methods). When incubating fixed purified human neutrophils
18 with MUB₄₀-Cy5, a fluorescent labelling was confirmed and appeared to be granular
19 (Figure 1G), suggesting that MUB₄₀ target was stored in neutrophil granules.
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34
35 We further confirmed that regardless of the fluorophore conjugated to MUB₄₀
36 (MUB₄₀-Cy5 or MUB₄₀-Dylight405, see Supplementary Methods), human neutrophil
37 granules were specifically labeled (Figure 2A). Neutrophils differentiate from
38 pluripotent haematopoietic stem cells (HSC, CD34+) in the bone marrow during
39 granulopoiesis, characterized by the formation of promyelocytes, myelocytes,
40 metamyelocytes, band cells, segmented neutrophilic cells, and mature neutrophils.
41 To assess the specificity of mature neutrophil labelling with MUB₄₀-Cy5,
42 hematopoietic stem cells were purified from cytopheresis product and differentiated
43 to neutrophils (see Supplementary Methods). We confirmed that MUB₄₀-Cy5 did not
44 label human hematopoietic stem cells until their differentiation into mature
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 neutrophils *in vitro* (Figure 2B). In order to anticipate its use in the presence of living
2 cells, a non-cleavable retro-inverso version of MUB₄₀, named RI-MUB₄₀, was
3
4 synthesized with non-natural D-amino acids. RI-MUB₄₀ was resistant to trypsin
5 proteolysis, whereas MUB₄₀ was rapidly degraded (Figure 2C-D). The neutrophil
6
7 granule binding property of RI-MUB₄₀ conjugated to Cy5 (RI-MUB₄₀-Cy5) was similar
8
9 to MUB₄₀-Cy5 (Figure 2A).
10
11

12 The specificity of neutrophil labeling with MUB₄₀ conjugated peptides was further
13
14 assessed on human and mouse blood samples. We demonstrated by flow cytometry
15
16 that human neutrophils were efficiently labeled with MUB₄₀-Alexa405 after cell
17
18 fixation and permeabilization; naïve cells were not labeled (Figure 3A). This result
19
20 was consistent with the localization of MUB₄₀-Alexa405 target in neutrophil granules
21
22 and the inability of MUB₄₀-Alexa405 to cross plasma membrane. Following the same
23
24 procedure, peripheral blood mononuclear cells (PBMCs) were not labeled with
25
26 MUB₄₀-Alexa405 (Figure 3B), as confirmed by immunofluorescent labeling (Figure
27
28 S2A). Similarly, among mouse circulating leucocytes, neutrophils were specifically
29
30 labeled with MUB₄₀-Alexa405, after fixation and permeabilization, not PBMCs
31
32 (including B-lymphocytes, T-lymphocytes, Ly6C-/± monocytes, Figure 3C and S2B-
33
34 C).
35
36

37 We demonstrate that all mammalian neutrophils tested were efficiently labeled with
38
39 MUB₄₀-Cy5, as illustrated with mouse, but also guinea pig circulating neutrophils
40
41 (Figure 3D). In animal models of shigellosis (see Supplementary Methods),
42
43 neutrophils recruited to the intestinal mucosa infected with *Shigella* were specifically
44
45 labeled with MUB₄₀-Cy5 or MUB₄₀-Dylight405, as illustrated in guinea pig colon
46
47 (*Shigella flexneri*; MUB₄₀-Cy5 or MUB₄₀-Dylight405, Figure 3E), mouse colon
48
49 (*Shigella sonnei*, MUB₄₀-Cy5, Figure 3F, described in (Anderson et al., 2017)), and
50
51
52
53
54
55
56
57
58
59
60

1 rabbit ileum (*Shigella flexneri*, MUB₄₀-Dylight405, Figure S3).

2 These results confirm the potential use of MUB₄₀ peptide as a specific neutrophil
3 marker in physiological and pathophysiological conditions, in humans and in various
4 animal models. We next aimed at identifying the specific MUB₄₀ target in neutrophil
5 granules.
6
7
8
9
10

11 **MUB₄₀ binds to lactoferrin stored in specific and tertiary granules**

12 The four classes of neutrophil granules (α , β 1, β 2, and γ) were fractionated on a
13 three-layer Percoll gradient (see Methods), as previously described (Kjeldsen et al.,
14 1999). To confirm the appropriateness of the approach we subjected the different
15 fractions to mass spectrometry and could identify the most abundant proteins stored
16 in each granule population (see Supplementary Methods): cathepsin G, neutrophil
17 elastase, and myeloblastin in azurophil granules; lactoferrin, NGAL, cathelicidin C,
18 and lysozyme C in specific granules; and lactoferrin, MMP-9, NGAL, cathelicidin C,
19 and protein S100-A9 in tertiary granules, as previously reported (Figure 4A, S4 and
20 Table S1).
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 The MUB₄₀ target was mainly stored in specific (β 1) and tertiary (β 2) granules, as
40 revealed by western blot using a biotinylated version of RI-MUB₄₀ (RI-MUB₄₀-biotin)
41 (see Supplementary Methods) when granule contents were analyzed on SDS Page
42 gel (Figure 4A) or on Ag-Page gel (allowing the separation of high molecular-weight
43 complexes, see Supplementary Methods) (Figure 4B). Both approaches allowed the
44 detection of a signal in β 1/ β 2 fractions with RI-MUB₄₀-Biotin suggested that MUB₄₀
45 target were present in these samples. A stronger signal was observed when
46 separating samples on Ag-Page, suggesting that MUB₄₀ target may form or be
47 associated with high molecular complexes or aggregates. The detection of a signal
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 on Ag-Page in the γ fraction with RI-MUB₄₀-Biotin might be due to an incomplete
2 fractionation of the complexes with this standard procedure (Figure 4B). The
3
4 propensity of lactoferrin, specifically stored in β 1/ β 2 fractions, to polymerize in the
5 presence of cations such as Ca²⁺ or Fe³⁺ (Bennett et al., 1981)(Mantel et al., 1994)
6
7 is hypothesized to be responsible of this phenomenon. The granule fractionation
8
9 stringency was assessed by immunodetecting lactoferrin exclusively in specific (β 1)
10 and tertiary (β 2) granules (Figure 4A).

11
12 Lactoferrin was identified as a target of MUB₄₀ in neutrophil granules, by a pulldown
13 assay with RI-MUB₄₀-Biotin (Figure 4C). This result was confirmed by
14 immunofluorescence experiments on fixed human neutrophils, showing a similar
15 localization of the RI-MUB₄₀-Cy5 and α -lactoferrin fluorescent signals (Figure 4D).
16
17 The MUB₄₀ lactoferrin-binding property was finally demonstrated with human purified
18 lactoferrin incubated in a RPMI 1640 medium supplemented with 10 mM HEPES and
19
20 3 mM glucose, which allowed the formation of lactoferrin oligomers, as previously
21 performed in other medium (Bennett et al., 1981)(Mantel et al., 1994). Again, in this
22 experimental model, a similar localization of the RI-MUB₄₀-Cy5 and α -lactoferrin
23 fluorescent signals was observed (Figure 4E). N-deglycosylation of lactoferrin with
24 PNGase abolished MUB₄₀-Cy5 labeling, suggesting that lactoferrin glycosylation
25 moiety was essential for MUB₄₀ binding to lactoferrin (Figure 4E-F).

26
27 As a conclusion, MUB₄₀ is a marker of lactoferrin, which is the most abundant protein
28 stored in neutrophil specific and tertiary granules. The potential use of MUB₄₀-Cy5 as
29 a marker of lactoferrin secretion was further assessed during *Shigella flexneri*
30 infection *in vitro* and in *in vivo* models of inflammation.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Detection of lactoferrin degranulation with MUB₄₀-Cy5 *in vitro* and *in vivo*

1
2 Neutrophil granule inducible exocytosis (or degranulation) occurs in the presence of
3
4 an inflammatory stimulus, such as bacterial infection. Here, for the first time, the
5
6 degranulation process could be assessed *in vitro* on living neutrophils infected with
7
8
9 *Shigella flexneri* by live fluorescence microscopy in the presence of RI-MUB₄₀-Cy5:
10
11 transient, dot-shaped fluorescent signals were detected on the cells' surface (Figure
12
13 5A and Movie S1), strongly suggesting that exocytosed lactoferrin was bound
14
15 extracellularly to RI-MUB₄₀-Cy5. Since RI-MUB₄₀-Cy5 was not degraded by
16
17 proteases (Figure 2C-D), the fact that transient lactoferrin labeling might be due to its
18
19 solubilization in the culture medium leading to the dilution of the fluorescent signal.
20
21
22 Lactoferrin detection with RI-MUB₄₀-Cy5 was strictly extracellular, confirming that this
23
24 marker does not cross plasma membrane of live cells, similarly to MUB₇₀ (Coïc et al.,
25
26 2012). *In vivo*, neutrophil lactoferrin secretion was successfully revealed on fixed
27
28 tissues with MUB₄₀-Cy5 in the guinea pig colonic mucosa infected by *Shigella*
29
30 *flexneri*; revealing lactoferrin accumulation within the bacteria foci vicinity (Figure
31
32 5B), consistent with previous studies (Masson et al., 1969). The assessment of
33
34 neutrophil recruitment during *Shigella flexneri* invasion could not be investigated in
35
36 the guinea pig model of shigellosis, since the targeted organ deep localization is not
37
38 compatible with fluorescence imaging techniques on living animals.
39
40
41
42
43
44

45
46 Further validation of RI-MUB₄₀ in living animals suffering of shigellosis was not
47
48 possible due to the localization of the infected organ, the colon, deep into the
49
50 abdomen, making the assessment of fluorescent signals difficult. Alternatively, the
51
52 capacity of RI-MUB₄₀ to specifically label inflammatory tissues was evaluated in an
53
54 arthritis mouse model (sterile inflammation), using the K/BxN serum transfer model
55
56 (Bruhns et al., 2003). Indeed, following systemic administration (i.v. injection) of RI-
57
58
59

1 MUB₄₀-Cy5 into arthritic mice, but not their naïve controls, a fluorescent signal
2 accumulated at inflammatory sites, localized in joints, which are known to contain a
3 large population of activated neutrophils and are hypothesized to contain a high
4 concentrated level of lactoferrin (Figure 5C). The inflammation in articulations was
5 confirmed by the detection of luminol (a MPO substrate, i.v. injection)
6 bioluminescence (Figure 5C). Notably, epifluorescent (RI-MUB₄₀-Cy5) and
7 bioluminescent (luminol) signals were significantly higher in arthritic mice compared
8 to controls (Figure 5C, $p \leq 0.0001$, T-test) and correlated (Figure 5D, $p \leq 0.0001$, T-
9 test).

10
11
12 In conclusion, we demonstrated here that MUB₄₀ and RI-MUB₄₀ peptides allowed the
13 assessment of neutrophil lactoferrin detection *in vitro* or *in vivo*. Therefore, the
14 potential use of RI-MUB₄₀ as an inflammatory disease marker, associated with
15 neutrophil recruitment and activation, was further evaluated on human inflamed
16 tissues.

17 **Neutrophil labeling with MUB₄₀ on human inflamed tissues**

18
19
20 Our results indicated that neutrophil lactoferrin could be labeled with MUB₄₀ or RI-
21 MUB₄₀ peptides intracellularly on fixed samples (cells and tissues) or extracellularly
22 upon its secretion by living neutrophils upon activation. Neutrophil recruitment and
23 activation was further successfully assessed on various human biopsies from
24 patients diagnosed with sterile or infectious inflammatory diseases with MUB₄₀ and
25 illustrated here with a malignant fibrous histiocytoma (Figure 6A) and a streptococcal
26 skin abscess (Figure 6B), respectively. In both cases, recruited neutrophils and
27 secreted lactoferrin were labeled with MUB₄₀-Cy5 and a α -lactoferrin antibody:
28 corresponding fluorescent signals were co-localized (Figure 6A-B, $p \leq 0.001$, T-test).

1 In conclusion we demonstrated that MUB₄₀ peptides allow detection of human
2 lactoferrin and therefore offers a new tool for the assessment of neutrophil
3 recruitment and activation in human inflammatory tissues.
4
5
6
7
8

9 **Discussion**

10 Here we designed, synthesized and validated MUB₄₀ and RI-MUB₄₀ peptides as
11 novel markers of neutrophil lactoferrin, which may be considered as universal
12 markers of mammalian neutrophils and will facilitate neutrophil detection and study in
13 animal models of inflammation, including mouse, rabbit, or guinea pig (Figures 3 and
14 S3), as illustrated by our recent report in guinea pigs (Arena et al., 2016).
15
16

17 As a novel lactoferrin marker, MUB₄₀ will contribute to a better understanding of
18 lactoferrin modulatory and antimicrobial functions *in vitro* and *in vivo*. To date, most
19 studies have focused on the importance of mucus lactoferrin in the protection of the
20 respiratory tract from inflammation or infection *in vivo* (Valenti et al., 2011)(Sagel et
21 al., 2009)(Dubin et al., 2004) or in lung epithelial cell culture models (Calu3 (Babu et
22 al., 2004)). Lactoferrin abundance and function in the intestinal tract has been less
23 investigated, although confirmed in humans (Peen et al., 1996); its protective role
24 was confirmed in a mouse model of colitis (Ye et al., 2014). The resistance of
25 lactoferrin to bacteria secreted serine proteases (SPATE) proteolysis strongly
26 support its importance in preserving the epithelial lineage from bacterial aggression
27 (Gutierrez-Jimenez et al., 2008). The use of MUB₄₀ will promote lactoferrin studies in
28 intestinal inflammation and infection.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 We previously characterized MUB₇₀ colonic mucus-binding property mediated by its
55 ability to interact with a Mucin 2 glycosylation moiety (Coïc et al., 2012). Here we
56
57
58
59
60
61
62
63
64
65

1 have confirmed that its shorter derivative, MUB₄₀-Cy5, similarly labeled colonic
2 mucus and goblet cells' granules (Figure 1B, C and F). We demonstrated that MUB₇₀
3 (data not shown) and MUB₄₀ peptides labeled neutrophil granules (Figures 1F and
4 2A) by interacting with a lactoferrin glycosylation moiety (Figure 4E-F). Taken
5 together, these results raised the question of the specificity of MUB₇₀ and MUB₄₀
6 targets in mucus samples and in neutrophil granules. Muc2 and lactoferrin are both
7 present in the colonic mucus, and both play a key role in the protection of the colonic
8 mucosa from colitis (Ye et al., 2014)(Faure et al., 2004). For technical reasons, it
9 was not possible to isolate and purify either Muc2 or lactoferrin from the mucus
10 matrix, which is a complex and dense hydrogel. Considering that mucins are not
11 expressed by neutrophils, lactoferrin can be considered a specific target of MUB₄₀ in
12 neutrophil granules. This assumption is supported here by the demonstration of the
13 interaction between purified human lactoferrin and MUB₄₀ (Figure 4C and F).
14 However, we cannot rule out the possibility that MUB₄₀ may label lactoferrin present
15 in colonic mucus together with Muc2. Although difficult, further investigations will be
16 required to address the MUB₄₀ target specificity in colonic mucus.

17 Using RI-MUB₄₀-Cy5, we could reveal neutrophil degranulation for the first time in
18 inflammatory tissues *in vivo* with a non-invasive method (Figure 5C-D). Notably the
19 intensity of fluorescent signal correlated with disease severity, suggesting that RI-
20 MUB₄₀-Cy5 is not only a marker for inflammation *in vivo*, but also allows the
21 appreciation of inflammation intensity.

22 We demonstrated that MUB₄₀ is a specific neutrophil marker, which may be used, in
23 a broad range of *in vitro* assays. Further investigations will be required to validate RI-
24 MUB₄₀ as a potentially new inflammation marker *in vivo*, including a pre-clinical study
25 (toxicity, bioavailability, specificity and sensitivity of its lactoferrin-binding property).

1 Labeling RI-MUB₄₀ with radioactive elements may be envisaged for inflammation site
2 localization with non-invasive inflammation-imaging methods such as scintigraphy,
3 PET or SPECT (Wu et al., 2013) (Zhang et al., 2010) (Zhang et al., 2007) (Locke et
4 al., 2009).
5
6
7
8
9

10 11 **Significance**

12
13
14
15
16
17 Neutrophils are major players of the innate immune response during inflammation
18 and infection, although their detection remains difficult in animal models and
19 humans. Here we describe MUB₄₀ as a specific marker of neutrophils, binding to
20 lactoferrin, stored in specific and tertiary granules or released upon neutrophil
21 activation. MUB₄₀ and its retro-inverso derivative RI-MUB₄₀ allow the imaging of
22 neutrophils *in vitro* and *in vivo* in inflammation animal models; these markers will
23 open new doors in neutrophil study, non-invasive live imaging of inflammation and
24 diagnostic of inflammatory diseases.
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **Acknowledgements**

40
41
42
43 We are thankful to A.-M. Nicola and the Plate-Forme d'Imagerie Dynamique (Institut
44 Pasteur, Paris) for help with live imaging experiments. F.J. is an employee of the
45 Centre National de La Recherche Scientifique (CNRS). This work was supported by
46 the Fondation Laurette Fugain (LF-2015-15) (BSM) and ANR JCJC grants (ANR-17-
47 CE15-0012) (BSM) - (ANR-16-CE15-0012-01) (FJ).
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Material and Methods

MUB₄₀ peptides series synthesis

The synthesis were carried out on a 100μmoles scale on an ABI 433 synthesizer (Applied Biosystems, Foster City, CA) from a polystyrene AM-RAM resin and using conventional Fmoc chemistry. N-terminal acetylation was achieved by treating the peptide resins at the end of the synthesis with acetic anhydride for 30 minutes. As a result, all peptides were N-terminal amide and C-terminal acetylated. For the purpose of structural analysis (CD and gel filtration), MUB₄₀ peptides were submitted to a N-ethyl maleimide treatment in order to prevent covalent dimer formation. Fluorophore labeling and biotin derivatization were performed through the conjugation of their maleimide derivatives to the free sulfhydryle peptides. All purification steps and HPLC analysis were done by C18 Reverse Phase columns. Final characterization by electro-spray mass analysis were consistent with the expected masses (between brackets) : Cy5-labeled MUB₄₀#1: 5549.740 (5550.115); Cy5-labeled MUB₄₀#2: 5447.472 (5447.933); Cy5-labeled MUB₄₀#3: 5588.273 (5589.170); Cy5-labeled MUB₄₀#4: 5501.778 (5502.093); Cy5-labeled RI-MUB₄₀#1 (RI-MUB₄₀): 5551.265 (5550.115); Dylight 405-labeled MUB₄₀#1 (MUB₄₀-D405): 5519,849 (5518,9.. – restricted proprietary information); RI-MUB₄₀#1-Biotin (RI-MUB₄₀-Biotin): 5296.994 (5296.792). Detailed synthesis and derivatization steps and the biophysical analysis of MUB₄₀ peptides are described in Supplementary Methods.

Neutrophil granules purification and fractionation.

Neutrophil granules were collected from purified polymorphonuclear neutrophils,

1 following the procedure described previously(Kjeldsen et al., 1999). Neutrophils were
2 resuspended in PBS ($2.7 \cdot 10^6$ cell/mL) with 0.5 μ L/mL DFP (Sigma-Aldrich) and
3
4 incubated on ice for 15 min prior centrifugation (1300 rpm; 10 min). Cells were
5
6 resuspended ($20 \cdot 10^6$ cell/mL) in a relaxation buffer (KCl 100 mM, NaCl 3 mM, MgCl₂
7
8 3.5 mM, PIPES 10 mM, adjusted at pH 6.8) with a cocktail of protease inhibitors (400
9
10 mM leupeptin, 400 mM pepstatin, 3 mM PMSF, 1 mM orthovanadate) and
11
12 supplemented with 1 mM ATP, 1 mM EDTA, and 1.25 mM EGTA. Cells were lysed
13
14 by nitrogen cavitation (350 psi, 20 min). Cell lysates were centrifuged at 3000 rpm for
15
16 15 min to remove remaining cells and nuclei. For total granule recovery, lysates were
17
18 centrifuged at 16000 rpm for 45 min; granules were resuspended in protease
19
20 inhibitor-containing relaxation buffer (described above) and stored at -80°C. For
21
22 granule fractionation, lysates were centrifuged onto a 3-layers Percoll gradient
23
24 (densities 1.120 g/mL - 1.090 g/mL - 1.050 g/mL) at $37.000 \times g$ for 30 min at 4°C, as
25
26 described in (Kjeldsen et al., 1999). From the top to the bottom, γ (secretory
27
28 vesicles), β 2 (tertiary granules), β 1 (specific granules), and α (azurophil granules)
29
30 fractions were collected. Remaining Percoll solution was removed by
31
32 ultracentrifugation ($100.000 \times g$ for 90 min at 4°C); purified granules were collected in
33
34 inhibitor-containing relaxation buffer and stored at -80°C.
35
36
37
38
39
40
41
42
43
44
45

46 **Human and mouse models of inflammation**

47
48
49 *Colon explant surgical collection.* In summary, human colon segments (ascending,
50
51 descending, and sigmoid colon) were obtained from fully informed patients
52
53 undergoing surgery for colon carcinoma and were analyzed anonymously. Patient
54
55 written consent was obtained, according to the French bioethics law. None of the
56
57
58
59
60
61
62
63
64
65

1 patients had undergone radiotherapy or chemotherapy. According to the
2 pathologist's examination rules for the longitudinally bisected colon, a healthy
3 segment of tissue, which was distant from the tumor region and devoid of metastatic
4 cells, was removed. Tissues were processed according to the French Government
5 guidelines for research on human tissues and the French Bioethics Act with the
6 authorization n°RBM 2009-50.
7
8
9

10
11
12
13
14
15 *Human inflammatory tissues.* Human biopsies from patients diagnosed for malignant
16 fibrous histiocytoma and for a streptococcal skin abscess were collected and
17 processed at the Kremlin Bicêtre Hospital, Anatomy and Pathological Histology
18 Department, headed by Dr. Thierry Larzure. Tissue samples were fixed in
19 formaldehyde and further embedded in paraffin. 10 µm sections were obtained using
20 a microtome (Leica Biosystem). Tissues were labeled with a mouse anti-lactoferrin
21 primary monoclonal antibody (Hycult biotech, clone 265-1K1, 1:50 dilution), MUB₄₀-
22 Cy5 (1 µg/mL), and Dapi (1:1000 dilution) as described below.
23
24
25
26
27
28
29
30
31
32
33
34
35

36 *Ex vivo infection of human colonic tissue.* Human colon explants were infected with
37 *S. flexneri* 5a (M90T) pGFP, as described in (Nothelfer et al., 2014) and adapted
38 from(Coron et al., 2009). Briefly, colonic tissues were cut into ~5-cm² segments and
39 pinned flat, with the submucosa facing down, onto a 4% agarose layer in tissue
40 culture Petri dishes containing DMEM/F12 culture medium (Invitrogen)
41 supplemented with 10% FBS, glutamine, and 2.1 g/L NaHCO₃ (Sigma-Aldrich). *S.*
42 *flexneri* (M90T) 5a pGFP was added at ~2 × 10⁸ bacteria per cm² of tissue. Bacteria
43 were allowed to settle for 15 min at room temperature before incubation at 37°C, 5%
44 CO₂ for 6 h on a slowly rocking tray. Tissue was fixed by overnight incubation with
45 4% PFA (Euromedex) and 0.1 M Hepes (Gibco) in PBS. For whole-mount staining,
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 tissues were fixed on a 40 × 11–mm tissue culture dish (TPP) with Histoacryl tissue
2 glue (Braun). To obtain 150-µm-thick sections, the tissue was embedded in low-
3 melting agarose according to (Snippert et al., 2011) and cut with a vibratome
4 (VT1000E; Leica).
5
6
7
8
9

10 *Mouse arthritis model.* 6-7 weeks old female C57BL/6J mice were purchased from
11 Charles River France, housed under specific pathogen-free (SPF) conditions and
12 handled in accordance with French and European directives. Mouse protocols were
13 approved by the Animal Ethics committee CETEA number 89 (Institut Pasteur, Paris,
14 France) and registered under #2013-0103, and by the French Ministry of Research
15 under agreement #00513.02. Arthritis was induced by i.v. injection of 120 µL K/BxN
16 serum and arthritis scored as described previously (Bruhns et al., 2003). Mice
17 injected with physiological saline were used as controls. On day 6 after serum
18 transfer, mice were anesthetized, shaved, depilated and injected i.p. with luminol (10
19 mg/mouse) and i.v. with 5 µg/mouse MUB-40 Cy5. Epifluorescence,
20 bioluminescence and CT images were acquired 10-90 min after injection using an
21 IVIS SpectrumCT (Perkin Elmer).
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Flow cytometry**

41 *Human.* Neutrophils and PBMCs were separated as described in Supplementary
42 Methods. Naïve cells were resuspended in PBS + EDTA 2mM. Fixed and
43 permeabilized were obtained by incubation in PFA 3.2% for 30 min and
44 resuspension in PBS + Triton 0.1% for 30 min. Naïve and fixed/permeabilized cells
45 were incubated with CD45-FITC and MUB₄₀-Alexa405 peptide (1 µL/mL) for 15 min
46 at room temperature. Cells were analyzed with a FACSCANTO II (BD) and data
47 were analyzed using Flowjo software.
48
49
50
51
52
53
54
55
56
57
58
59

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Mouse. Blood leucocytes were purified by dextran, washed in PBS EDTA and kept on ice. For hematopoietic populations staining, 2 to 3 million cells were resuspended in PBS EDTA, blocked with 16/32 for 15 minutes and stained with antibodies for 30 minutes at 4°C (CD45 PE-CF594, CD3e FITC, B220 PE-CY7, NKP46 FITC, CD11b PE from BD biosciences, and Ly6G APC-H7, Ly6C APC from Biolegend). Cells were washed with PBS EDTA and fixed in PFA 3.3% at room temperature during 15 minutes. Cells were washed and resuspended in PBS-0.1% Triton for 5 minutes. Cells were then incubated with MUB₄₀-Alexa405 peptide (1 μL/mL) for 15 minutes at RT and washed. Not fixed cells incubated with peptide or fixed cells not incubated with peptide were used as negative control. Cell fluorescence was determined using a Fortessa (BD biosciences) and analyzed with Kaluza Software (Beckman Coulter). The fluorescence intensity was quantified.

Fluorescent markers and cell labeling

Fixation and staining procedures. For microscopy studies, purified or cultured cells and polymerized lactoferrin were resuspended onto 24-well plates containing 12mm coverslips in RPMI 1640 + 10 mM Hepes (when cultured in the autologous plasma) and centrifuged at 300 x g for 10 min. Culture media were removed and cells were fixed in 4% Paraformaldehyde (PFA) for two hours. Fixed cells were washed three times in PBS + 0.1% saponin (Sigma-Aldrich), prior immunolabeling with primary antibodies in the same buffer for 1 hour (Triton 0.1% can alternatively be used for cell permeabilization). After three additional washes in PBS + 0.1% saponin, secondary antibodies and fluorescent markers were incubated for one hour.

1 Coverslips were washed three time in PBS + 0.1% saponin, three times in PBS, and
2 three times in deionized H₂O and mounted with prolong gold™ mounting media.
3

4 *Antibodies, fluorescent markers.* For immunofluorescence assay, lactoferrin was
5 detected with a mouse anti-lactoferrin primary monoclonal antibody (Hycult biotech,
6 clone 265-1K1, 1:50 dilution) and an anti-mouse-FITC conjugated secondary
7 antibody (1:1000). Nuclei were detected with DAPI (Life Technologies), Lyophilized
8 MUB₄₀ peptides (MUB₄₀#1-Cy5, MUB₄₀#2-Cy5, MUB₄₀#3-Cy5, MUB₄₀#4-Cy5,
9 MUB₄₀#1-Dylight, RI-MUB₄₀-Cy5, and RI-MUB₄₀-Biotin) were solubilized in a
10 phosphate buffer pH8 at a 1 mg/mL concentration and used at a 1:1000 dilution. For
11 PBMC staining CD19-APC (B lymphocytes), CD3-APC (T lymphocytes), and CD14-
12 PercP (monocytes, macrophages) (BD Bioscience) were used at a 1:1000 dilution
13 together with Dapi (1:1000) and MUB₄₀-Cy5 (1 mg/mL). Actin was stained with
14 Phalloidin-Rhodamine red X (RRX) (Jackson Immunoresearch Antibodies) used at a
15 1:1000 final dilution.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **Biochemistry**

38 *Electrophoresis.* Proteins were separated by either SDS Page (4-12% gradient, at
39 150 volts for 90 min) or Ag-Page (0.7 % (w/v) agarose gels in 1 x TAE (40 mM Tris-
40 acetate, 1 mM EDTA pH 8), containing 0.1% (w/v) SDS at 65 volts for 3 hours).
41
42
43
44
45
46

47 *Transfer.* Protein samples separated by SDS Page were transferred to nitrocellulose
48 membrane performing electrophoretic protein transfer. Protein samples separated by
49 Ag-Page were transferred to nitrocellulose membrane using a vacuum blotter (GE
50 HealthCare); 40 mbar pressure in 4 x SSC (0.6 M sodium chloride, 60 mM tri-sodium
51 citrate).
52
53
54
55
56
57
58
59

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

RI-MUB₄₀-Biotin immunoblotting. Transferred nitrocellulose membranes were blotted in PBS with RI-MUB₄₀-Biotin (1 µg/mL) for 3 hours, washed three times (15 min) in PBS, incubated with HRP-conjugated Streptavidin (Thermo Scientific ref. N100, 1:1000 dilution) for one hour, and washed three times (15 min) in PBS. RI-MUB₄₀-Biotin binding was detected with chemiluminescence (ECL kit, GE Healthcare) using a an imaging system (B:Box, Syngene).

RI-MUB₄₀-Biotin Pulldown assay. Lyophilized, biotinylated retro-inverso MUB₄₀ (RI-MUB₄₀-Biotin) was solubilized in 1 mL (185 µg/ml final concentration) of binding buffer (20 mM NaH₂PO₄, 0.15 M NaCl, pH 7.5). 150 µL (277 ng) of solubilized RI-MUB₄₀-Biotin was loaded onto 200 µL of washed/packed Streptavidin Sepharose High Performance beads (GE HealthCare). The loaded beads were incubated with gentle rocking for 1 hour at room temperature with 1 mg of purified neutrophil granule fractions. Pulldown fractions were transferred to columns and washed with 10 mL fresh binding buffer. Bound RI-MUB₄₀-Biotin and co-purified proteins were eluted with 500 µL 8M Guanidine-HCl, pH 1.5. Eluted proteins were mixed 1:1 with 2x Laemmli buffer (4% SDS, 20% Glycerol, 10% 2-mercaptoethanol, 0.004% bromophenol blue, and 0.125 M Tris HCl, pH 6.8). Samples were run on 4-20% SDS-Page gels and stained with InstantBlue™ (Expedeon , ref. ISB1L) for 1 hour before destaining in deionized H₂O. Stained gels were imaged and ≈80 kDa co-purified band was cut out and sent for mass spectrometry identification.

Lactoferrin polymerization. Human purified lactoferrin (ref : L1294, Sigma-Aldrich) was resuspended in deionized H₂O (35 µg/mL). Lactoferrin was incubated in RPMI + 10 mM Hepes supplemented with 10 mM FeCl₃, at indicated concentrations (0.35 or 3.5 µg/mL) onto 24-well plates containing 12mm coverslips overnight at 37°C,

1 adapted from similar lactoferrin polymerization experiments performed in iron
2 saturated phosphate buffer(Mantel et al., 1994).
3

4 *Lactoferrin deglycosylation.* About 10 µg of human purified lactoferrin (ref : L1294,
5 Sigma-Aldrich) was treated by Peptide-N-Glycosidase F (PNGaseF, New England
6 Biolabs, Ipswich MA, USA) for N-deglycosylation. Protein was treated exactly as
7 described in manufacturer protocol. Twelve unit of PNGase F were added for 4 h at
8 37°C for the removal of N-glycosylation.
9

10 *Lactoferrin polymers interaction with MUB₄₀-Cy5.* Lactoferrin polymers were
11 centrifuged at 2000 rpm for 10 min and fixed in Paraformaldehyde (PFA) 4% for one
12 hour. Lactoferrin polymers were immunolabeled in PBS + 0.1% saponin (Sigma-
13 Aldrich) with a mouse anti-lactoferrin primary monoclonal antibody (Hycult biotech,
14 clone 265-1K1, 1:50 dilution) and an anti-mouse-FITC conjugated secondary
15 antibody (1:1000), together with MUB₄₀-Cy5 (1µg/mL). Slides were washed three
16 times in PBS and three times in deionized H₂O and mounted with prolong gold™
17 mounting media.
18

19 *Lactoferrin polymers interaction with RI-MUB₄₀-Biotin.* 5 µg lactoferrin polymers pre-
20 formed in RPMI 1640 +10 mM Hepes (see above) were separated by Ag-Page,
21 transferred to nitrocellulose membrane and blotted with RI-MUB₄₀-Biotin (1µg/mL) in
22 PBS, as described above.
23
24
25
26
27
28
29
30
31
32
33
34
35

36 **Author contributions**

37 YMC and FB synthesized MUB₄₀ peptides. BB performed biophysical analyses. MA,
38 JS, LI, CR, DT and TCB performed biochemical and mass spectrometry analyses.
39 NL and VL performed HSC experiments. MA, PV, ETA, JYT, GN, KN, FJ and BSM
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 validated MUB₄₀ peptides in indicated animal models. TL validated MUB₄₀ peptides
2 in human biopsies. BSM designed the experiments and wrote the manuscript
3
4
5 together with FB, FJ and MM.
6
7
8
9

10 **Competing financial interests**

11
12
13
14 The authors declare no competing financial interests
15
16
17
18
19
20

21 **Materials & Correspondence**

22
23
24 Correspondence and material request (including MUB₄₀ peptide derivatives) should
25
26 be addressed to Dr. Benoit Marteyn
27
28
29
30
31
32
33

34 **Bibliography**

35
36
37 Anderson, M.C., Vonaesch, P., Saffarian, A., Marteyn, B.S., and Sansonetti, P.J.
38 (2017). *Shigella sonnei* Encodes a Functional T6SS Used for Interbacterial
39 Competition and Niche Occupancy. *Cell Host Microbe* 21, 769–776.e3.
40

41
42 Arena, E.T., Tinevez, J.-Y., Nigro, G., Sansonetti, P.J., and Marteyn, B.S. (2016).
43 The infectious hypoxia: Occurrence and causes during *Shigella* infection. *Microbes*
44 *Infect.*
45

46
47 Babu, P.B.R., Chidekel, A., and Shaffer, T.H. (2004). Protein composition of apical
48 surface fluid from the human airway cell line Calu-3: effect of ion transport mediators.
49 *Clin. Chim. Acta* 347, 81–88.
50

51
52 Bennett, R.M., Bagby, G.C., and Davis, J. (1981). Calcium-dependent polymerization
53 of lactoferrin. *Biochem. Biophys. Res. Commun.* 101, 88–95.
54

55
56 Borregaard, N., Sørensen, O.E., and Theilgaard-Mönch, K. (2007). Neutrophil
57 granules: a library of innate immunity proteins. *Trends Immunol.* 28, 340–345.
58

59
60 Bruhns, P., Samuelsson, A., Pollard, J.W., and Ravetch, J.V. (2003). Colony-
61
62
63
64
65

stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. *Immunity* 18, 573–581.

Coïc, Y.-M., Baleux, F., Poyraz, Ö., Thibeaux, R., Labruyere, E., Chretien, F., Sobhani, I., Lazure, T., Wyplosz, B., Schneider, G., et al. (2012). Design of a specific colonic mucus marker using a human commensal bacterium cell surface domain. *J. Biol. Chem.* 287, 15916–15922.

Coron, E., Flamant, M., Aubert, P., Wedel, T., Pedron, T., Letessier, E., Galmiche, J.P., Sansonetti, P.J., and Neunlist, M. (2009). Characterisation of early mucosal and neuronal lesions following *Shigella flexneri* infection in human colon. *PLoS ONE* 4, e4713.

Cowland, J.B., and Borregaard, N. (2016). Granulopoiesis and granules of human neutrophils. *Immunol. Rev.* 273, 11–28.

Däbritz, J., Musci, J., and Foell, D. (2014). Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. *World J. Gastroenterol.* 20, 363–375.

Dubin, R.F., Robinson, S.K., and Widdicombe, J.H. (2004). Secretion of lactoferrin and lysozyme by cultures of human airway epithelium. *Am. J. Physiol. Lung Cell Mol. Physiol.* 286, L750–L755.

Faure, M., Moennoz, D., Mettraux, C., Montigon, F., Schiffrin, E.J., Obled, C., Breuille, D., and Boza, J. (2004). The chronic colitis developed by HLA-B27 transgenic rats is associated with altered in vivo mucin synthesis. *Dig Dis Sci* 49, 339–346.

Faurschou, M., and Borregaard, N. (2003). Neutrophil granules and secretory vesicles in inflammation. *Microbes Infect.* 5, 1317–1327.

Gouni-Berthold, I., Baumeister, B., Wegel, E., Berthold, H.K., Vetter, H., and Schmidt, C. (1999). Neutrophil-elastase in chronic inflammatory bowel disease: a marker of disease activity? *Hepatogastroenterology* 46, 2315–2320.

Gutierrez-Jimenez, J., Arciniega, I., and Navarro-Garcia, F. (2008). The serine protease motif of Pic mediates a dose-dependent mucolytic activity after binding to sugar constituents of the mucin substrate. *Microb. Pathog.* 45, 115–123.

Ho, A.-S., Chen, C.-H., Cheng, C.-C., Wang, C.-C., Lin, H.-C., Luo, T.-Y., Lien, G.-S., and Chang, J. (2014). Neutrophil elastase as a diagnostic marker and therapeutic target in colorectal cancers. *Oncotarget* 5, 473–480.

Kjeldsen, L., Sengelov, H., and Borregaard, N. (1999). Subcellular fractionation of human neutrophils on Percoll density gradients. *J. Immunol. Methods* 232, 131–143.

Lehmann, F.S., Burri, E., and Beglinger, C. (2015). The role and utility of faecal markers in inflammatory bowel disease. *Therap Adv Gastroenterol* 8, 23–36.

Locke, L.W., Chordia, M.D., Zhang, Y., Kundu, B., Kennedy, D., Landseadel, J., Xiao, L., Fairchild, K.D., Berr, S.S., Linden, J., et al. (2009). A novel neutrophil-

specific PET imaging agent: cFLFLFK-PEG-64Cu. *J. Nucl. Med.* 50, 790–797.

Mantel, C., Miyazawa, K., and Broxmeyer, H.E. (1994). Physical characteristics and polymerization during iron saturation of lactoferrin, a myelopoietic regulatory molecule with suppressor activity. *Adv. Exp. Med. Biol.* 357, 121–132.

Martins, C.A., Fonteles, M.G., Barrett, L.J., and Guerrant, R.L. (1995). Correlation of lactoferrin with neutrophilic inflammation in body fluids. *Clin. Diagn. Lab. Immunol.* 2, 763–765.

Masson, P.L., Heremans, J.F., and Schonke, E. (1969). Lactoferrin, an iron-binding protein in neutrophilic leukocytes. *J. Exp. Med.* 130, 643–658.

Nothelfer, K., Arena, E.T., Pinaud, L., Neunlist, M., Mozeleski, B., Belotserkovsky, I., Parsot, C., Dinadayala, P., Burger-Kentischer, A., Raqib, R., et al. (2014). B lymphocytes undergo TLR2-dependent apoptosis upon *Shigella* infection. *J. Exp. Med.* 211, 1215–1229.

Orsi, N. (2004). The antimicrobial activity of lactoferrin: current status and perspectives. *Biometals* 17, 189–196.

Peen, E., Eneström, S., and Skogh, T. (1996). Distribution of lactoferrin and 60/65 kDa heat shock protein in normal and inflamed human intestine and liver. *Gut* 38, 135–140.

Sagel, S.D., Sontag, M.K., and Accurso, F.J. (2009). Relationship between antimicrobial proteins and airway inflammation and infection in cystic fibrosis. *Pediatr. Pulmonol.* 44, 402–409.

Sagel, S.D., Wagner, B.D., Anthony, M.M., Emmett, P., and Zemanick, E.T. (2012). Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. *Am. J. Respir. Crit. Care Med.* 186, 857–865.

Sansonetti, P.J., Arondel, J., Huerre, M., Harada, A., and Matsushima, K. (1999). Interleukin-8 controls bacterial transepithelial translocation at the cost of epithelial destruction in experimental shigellosis. *Infect. Immun.* 67, 1471–1480.

Sengelov, H., Follin, P., Kjeldsen, L., Lollike, K., Dahlgren, C., and Borregaard, N. (1995). Mobilization of granules and secretory vesicles during in vivo exudation of human neutrophils. *J. Immunol.* 154, 4157–4165.

Sipponen, T. (2013). Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin. *Dig Dis* 31, 336–344.

Snippert, H.J., Schepers, A.G., Delconte, G., Siersema, P.D., and Clevers, H. (2011). Slide preparation for single-cell-resolution imaging of fluorescent proteins in their three-dimensional near-native environment. *Nat Protoc* 6, 1221–1228.

Soehnlein, O., Weber, C., and Lindbom, L. (2009). Neutrophil granule proteins tune monocytic cell function. *Trends Immunol.* 30, 538–546.

1 Stragier, E., and Van Assche, G. (2013). The use of fecal calprotectin and lactoferrin
2 in patients with IBD. Review. *Acta Gastroenterol. Belg.* 76, 322–328.

3 Sugi, K., Saitoh, O., Hirata, I., and Katsu, K. (1996). Fecal lactoferrin as a marker for
4 disease activity in inflammatory bowel disease: comparison with other neutrophil-
5 derived proteins. *Am. J. Gastroenterol.* 91, 927–934.

6
7
8 Valenti, P., Catizone, A., Pantanella, F., Frioni, A., Natalizi, T., Tendini, M., and
9 Berlutti, F. (2011). Lactoferrin decreases inflammatory response by cystic fibrosis
10 bronchial cells invaded with *Burkholderia cenocepacia* iron-modulated biofilm. *Int J*
11 *Immunopathol Pharmacol* 24, 1057–1068.

12
13
14 Wu, C., Li, F., Niu, G., and Chen, X. (2013). PET imaging of inflammation
15 biomarkers. *Theranostics* 3, 448–466.

16
17
18 Ye, Q., Zheng, Y., Fan, S., Qin, Z., Li, N., Tang, A., Ai, F., Zhang, X., Bian, Y., Dang,
19 W., et al. (2014). Lactoferrin deficiency promotes colitis-associated colorectal
20 dysplasia in mice. *PLoS ONE* 9, e103298.

21
22
23 Zhang, Y., Kundu, B., Fairchild, K.D., Locke, L., Berr, S.S., Linden, J., and Pan, D.
24 (2007). Synthesis of novel neutrophil-specific imaging agents for Positron Emission
25 Tomography (PET) imaging. *Bioorg. Med. Chem. Lett.* 17, 6876–6878.

26
27
28 Zhang, Y., Xiao, L., Chordia, M.D., Locke, L.W., Williams, M.B., Berr, S.S., and Pan,
29 D. (2010). Neutrophil targeting heterobivalent SPECT imaging probe: cFLFLF-PEG-
30 TKPPR-99mTc. *Bioconjug. Chem.* 21, 1788–1793.

Figure legends

Figure 1. MUB₄₀, derived from MUB₇₀, binds to the human colonic mucus and neutrophil granules

(A) Schematic representation of the four 40-amino acid peptides named MUB₄₀#1, MUB₄₀#2, MUB₄₀#3, MUB₄₀#4, overlapping and covering the MUB₇₀ sequence (Coïc et al., 2012) (from C-terminal to N-terminal, see Figure S1A). (B) Human colonic mucus layer was labelled with the MUB₄₀#1-Cy5 fluorescent conjugate (1 µg/mL, magenta). Actin (red); bar, 10 µm; not MUB₄₀#2-#4 peptides conjugated to Cy5 (shown in Figure S1B). (C) Colonic goblet cell granules were labelled with MUB₄₀#1-Cy5 (1 µg/mL, magenta), which was not the case for MUB₇₀-Cy5 (Coïc et al., 2012) or MUB₄₀#2-#4 peptides (data not shown). Actin (red); bar, 20 µm. (D) Elution profiles of MUB₄₀ peptides (#1 - #4) were obtained by analytical gel filtration (absorbance at 280 nm). Samples were prepared at 10 µg/ml in the elution buffer (20 mM phosphate buffer, 150 mM NaCl, pH 7.4). MUB₄₀#1 assembled as a trimer, similarly to MUB₇₀ (Coïc et al., 2012), not MUB₄₀#2, MUB₄₀#3, and MUB₄₀#4. The relative masses (15,9 ; 22,0 ; 20,5 and 20,4 respectively) were estimated from standard proteins' elution volume (as indicated). (E) Far-UV Circular Dichroism spectra of the four MUB₄₀ peptides at 60 µM in 20 mM sodium phosphate buffer (pH 7,4) in the presence of 50 mM NaCl, showing a specific structural signal of MUB₄₀#1, compared to others peptides. (F) A human colonic explant was infected with *Shigella flexneri* pGFP (green) and labelled with MUB₄₀#1-Cy5 (1 µg/mL, magenta) and Dapi (blue) after fixation and permeabilization. The colonic mucus layer and infiltrated

1 neutrophils (see (G)), were labelled with MUB₄₀#1-Cy5, as imaged by two-photon
2 microscopy. Bar, 50 μm **(G)** The labelling of polymorphonuclear neutrophils with
3 MUB₄₀#1-Cy5 (1 μg/mL, magenta) was confirmed on human purified neutrophils,
4 showing a granular staining. Nucleus was stained with Dapi (blue). Bar, 5 μm.
5
6
7
8
9

10
11
12
13
14 **Figure 2. Mature myeloid cells were specifically labelled with MUB₄₀#1-Cy5**
15 **(hereafter named MUB₄₀-Cy5)**
16

17
18
19
20 **(A)** Human polymorphonuclear neutrophils were similarly labelled with MUB₄₀
21 conjugated with Cy5 (magenta) or Alexa405 (blue) and with a retro-inverso (RI)
22 MUB₄₀ peptide, designed with non-natural D-amino acids, conjugated with Cy5
23 (magenta). Nuclei were stained with Dapi (blue or white). Bars, 20 μm. **(B)** Human
24 hematopoietic stem cells (CD34+) were not labelled by MUB₄₀-Cy5 during their
25 proliferation, when a positive staining (magenta) was obtained upon their
26 differentiation in polymorphonuclear neutrophils in the presence of G-CSF, IL-3, and
27 IL-6 (2 weeks). Nuclei were stained with Dapi (blue). Bars, 50 μm. **(C-D)** RI-MUB₄₀
28 peptide was not degraded by trypsin. **(C)** MUB₄₀ and RI-MUB₄₀ final peptide
29 concentration was 0,25 mg/mL and trypsin to protein ratio was 1:20 (w/w). HPLC
30 profiles of purified MUB₄₀ and RI-MUB₄₀ peptides incubated with Trypsin during the
31 0, 1, 3, and 24h at 37°C. The percentage of peptide stability over the time are shown
32 in **(D)**. Results are expressed with Mean ± S.D. (n=3).
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 3. Specific labelling of neutrophils (human, mouse, guinea pig) with MUB₄₀ conjugated fluorescent peptides using flow cytometry or fluorescent imaging.

(A) Naïve (blue) and fixed/permeabilized human neutrophils (red) were incubated with MUB₄₀-Alexa405 (1 µg/mL) and analyzed by flow cytometry. The efficient labelling of fixed/permeabilized neutrophils with MUB₄₀-Alexa405 confirms its intracellular target. MFI were calculated with three independent samples, error bars show S.D., *** indicates $p < 0.001$. **(B)** Human neutrophils were separated on a Percoll gradient (see Supplementary Methods) and subsequently fixed and permeabilized. MUB₄₀-Alexa405 (1 µg/mL) specifically labels neutrophils, not PBMCs. MFI were calculated with three independent samples, error bars show S.D., *** indicates $p < 0.001$. **(C)** MUB₄₀-Alexa405 labelling of mouse leucocytes was assessed by flow cytometry. The gating strategy and negative control are described in Fig. S2B-C. MUB₄₀-Alexa405 (1 µg/mL) specifically labels neutrophils, not mononuclear cells, including B and T lymphocytes and Ly6C⁻ or Ly6C⁺ monocytes. MFI were calculated with three independent samples, error bars show S.D., ** indicates $p < 0.01$. Consistent results were obtained by immunofluorescent microscopy shown in Fig. S2A. **(D)** Guinea pig and mouse neutrophils were fixed and labelled with MUB₄₀-Cy5 (magenta). Nuclei were stained with Dapi (blue). Bars, 10 µm. **(E)** Upon *Shigella flexneri* 5a pGFP (green) infection of the guinea pig colonic mucosa, infiltrated neutrophils were labelled with MUB₄₀-Cy5 (magenta) or MUB₄₀-Alexa405 (blue). Bars, 100 µm. **(F)** Upon *Shigella sonnei* pMW211 (pDsRed) (red) oral challenge of mice, a local colonization of the colonic mucosa was observed,

1 associated with a recruitment of neutrophils labelled with MUB₄₀-Cy5 (magenta).
2 Actin was stained with Phalloidin-FITC (green), bar, 100 μm.
3
4
5
6
7
8

9 **Figure 4. MUB₄₀ binds specifically to lactoferrin, stored in neutrophil specific**
10 **(β1) and tertiary granules (β2)**
11

12
13
14 **(A)** Human neutrophil granules were purified and fractionated on a 3-layers Percoll
15 gradient (Kjeldsen et al., 1999). Total granule, α (azurophil granules), β1 (specific
16 granules), β2 (tertiary granules), and γ (secretory vesicles) fractions were separated
17 on a 10% SDS Page gel and stained with Coomassie. Most abundant proteins in
18 each fraction was identified by mass spectrometry (right panel) (raw data presented
19 in Figure S4 and Table S1). The preferential labelling of the β1 and β2 fractions with
20 RI-MUB₄₀-Biotin (1 μg/mL) together with a α-lactoferrin antibody was observed by
21 western blot using Streptavidin-HRP (bottom). **(B)** Granule fractions (α, β1, β2 and γ)
22 were additionally separated on an Ag-Page gel (allowing the identification of high
23 molecular-weight complexes) prior to transferring proteins onto a nitrocellulose
24 membrane. The preferential labelling of the β1 and β2 fractions with RI-MUB₄₀-Biotin
25 (1 μg/mL) was confirmed by western blot using Streptavidin-HRP. **(C)** Purified
26 neutrophil granules were incubated with RI-MUB₄₀-Biotin to identify its target. The
27 most abundant protein present in the output was identified by mass spectrometry as
28 lactoferrin (78 kDa). FT corresponds to the flow-through fraction **(D)** The labelling of
29 lactoferrin by MUB₄₀ was confirmed by immunofluorescence on fixed human
30 neutrophils, showing a co-localization of the fluorescent signals using RI-MUB₄₀-Cy5
31 (magenta) and a α-lactoferrin antibody (green). DNA was stained with Dapi, bar, 20
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

μm . **(E)** In order to confirm the labelling of human lactoferrin by MUB₄₀, commercial purified lactoferrin was allowed to polymerize in RPMI 1640 culture medium (0.35 $\mu\text{g}/\text{mL}$ and 3.5 $\mu\text{g}/\text{mL}$) at 37°C (adapted from (Bennett et al., 1981);(Mantel et al., 1994)). Polymerized lactoferrin was fixed and immunolabeled with MUB₄₀-Cy5 (magenta) and an α -lactoferrin antibody (green). bar, 20 μm . Deglycosylated lactoferrin (PNGase treatment) was no longer labelled by MUB₄₀-Cy5. **(F)** Lactoferrin (naïve and deglycosylated) polymers (5 μg) were separated on an Ag-Page gel prior to transfer onto a nitrocellulose membrane. The interaction between lactoferrin and MUB₄₀ was confirmed by western blot with RI-MUB₄₀-Biotin (1 $\mu\text{g}/\text{mL}$) and streptavidin-HRP.

Figure 5. Neutrophil lactoferrin degranulation assesement with RI-MUB₄₀-Cy5 *in vitro* and *in vivo* in infectious and sterile inflammation models


(A) The kinetics of the lactoferrin degranulation (cell surface exposure, white arrows) was assessed by live microscopy on neutrophils infected by *Shigella flexneri* pGFP (green) (at MOI 20) in the presence of RI-MUB₄₀-Cy5 (1 $\mu\text{g}/\text{mL}$, magenta) (RPMI 1640 medium supplemented with 10 mM HEPES at 37°C). Images were acquired every 60s for 9 min (see Movie S1), bar 10 μm . RI-MUB₄₀-Cy5 did not cross the plasma membrane of living cells (data not shown), similarly to MUB₇₀ (Coïc et al., 2012). **(B)** Neutrophil lactoferrin degranulation is detected in *Shigella flexneri* 5a pGFP (green) foci of infection in the guinea pig mucosa with MUB₄₀-Cy5 (1 $\mu\text{g}/\text{mL}$, magenta) (white arrow) DNA was stained with Dapi (blue). Bar, 20 μm . **(C-D)** RI-MUB₄₀-Cy5 accumulates at sites of inflammation *in vivo*. C57Bl/6J mice were

1 injected i.v. with serum from K/BxN mice (K/BxN, n=4) or saline (saline, n=5) (day 0).
2 **(C)** Photon emission corresponding to luminol degradation by myeloperoxidase
3 activity present in the joints was measured 6 days post arthritis induction (top
4 panels). Bioluminescence in regions of interest (red circles) is expressed as average
5 radiance (p/s/cm²/sr; left scatter plot). Accumulation of RI-MUB₄₀-Cy5 fluorescent
6 signal (640nm/700nm) in the joints of arthritic mice but not in control mice (middle
7 panels and lower panels as merged picture with CT). Epifluorescence in regions of
8 interest (red circles) is expressed as average radiant efficiency (p/s/cm²/sr/[uW/cm²];
9 right scatter plot). **(D)** Correlation of bioluminescent signal and RI-MUB₄₀-Cy5
10 fluorescent signal in indicated regions of interest (hind ankle joints). Data in (C) are
11 representative of two independent experiments. Error bars correspond to the SEM,
12 **** indicates $p \leq 0.0001$ (unpaired t-test).
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32


33 **Figure 6. Inflammatory tissues labelling with MUB₄₀-Cy5**

34
35
36 Tissue inflammation is characterized by neutrophil recruitment and potentially
37 associated with lactoferrin degranulation. The validation of MUB₄₀ peptides (here
38 MUB₄₀-Cy5) as markers of inflammation was confirmed on human biopsies, here **(A)**
39 a malignant fibrous hystiocytoma (sterile inflammation) and **(B)** a streptococcal skin
40 abscess (infectious inflammation). Lactoferrin was stained with an anti-lactoferrin
41 antibody (green) and MUB₄₀-Cy5 (1µg/mL, magenta), DNA was stained with Dapi
42 (blue). Bars, 150 µm. Surface plots and correlation of fluorescent signals were
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


Anderson et al., Fig. 1




Anderson et al., Fig. 3




Anderson et al., Fig. 4



Anderson et al., Fig. 5




Anderson et al., Fig. 6

A**Malignant fibrous histiocytoma**


Surface plot analysis



Dapi




Lactoferrin

MUB₄₀-Cy5**Correlation
Lactoferrin/MUB₄₀-Cy5**


Pearson r: 0.82

R²: 0.65


P value <0.001

B**Streptococcal skin abscess**


Surface plot analysis



Dapi



Lactoferrin

MUB₄₀-Cy5**Correlation
Lactoferrin/MUB₄₀-Cy5**

Pearson r: 0.87

R²: 0.74

P value <0.001

Anderson *et al*, Supplementary informations**Supplementary Figure legends****Supplementary Figure 1. MUB₄₀ peptides sequence and colonic mucus binding property**

(a) Operational sequences for the syntheses of MUB₄₀#1, MUB₄₀#2, MUB₄₀#3, MUB₄₀#4, where the secondary amino acid substitutes are indicated in red (dipeptides pseudoproline) or green (dipeptides Dmb). The proline residues are indicated in blue. (b) As described in Fig. 1b with MUB₄₀#1-Cy5, Human colonic mucus layer was labelled with the MUB₄₀#2-Cy5, MUB₄₀#3-Cy5, and MUB₄₀#4-Cy5 fluorescent conjugate (1 µg/mL, magenta). Actin (red) ; bar, 10 µm.

Supplementary Figure 2. Human or mouse peripheral blood mononuclear cells (PBMC) are not labeled by MUB₄₀-Cy5 or MUB₄₀-Alexa405

(A) Human PBMCs were purified from blood samples and fixed in PFA 3%. CD3⁺ (T lymphocyte), CD14⁺ (monocytes, macrophage), and CD19⁺ (B lymphocyte) cells (red) were not stained with MUB₄₀-Cy5 (magenta), using the same protocol as in Fig. 2D (neutrophils). Bars are 10 µm. (B) Gating strategy for identification of mouse hematopoietic cell populations in peripheral blood by flow cytometry. From total cells, CD45⁺ and singlets were selected. In a “Singlets” gate, neutrophils (Ly6G⁺) were selected. After exclusion of neutrophils, lymphoid cells were identified in a “Not neutro” gate, B lymphocytes (B220⁺), T lymphocytes (CD3⁺) and NK cells (NKP46⁺). After exclusion of lymphoid cells in a “not neutrophil not lymphoid” gate, monocytes were gated as CD11b⁺ cells and divided in two subsets, Ly6C⁺ classical and Ly6C⁻ patrolling monocytes. (C) Fluorescence intensity of MUB₄₀-Alexa405 peptide in

1 distinct hematopoietic cell populations from peripheral blood was acquired and Mean
2 fluorescence intensity (MFI) was calculated from three independent samples. Error
3 bars correspond to the SD, * indicates $p \leq 0.05$ (unpaired t-test).
4
5
6
7

8
9 **Supplementary Figure 3. Infiltrated neutrophil detection in the rabbit intestinal**
10 **mucosa**
11

12 Immunofluorescence detection of neutrophils (MMP-9, green) in a rabbit ileum
13 section. Actin was stained with RRX-phalloidin (red), and neutrophils were labeled
14 with MUB₄₀-Dylight405 (blue) at a final concentration of 1 $\mu\text{g}/\text{mL}$ and a anti-
15 gelatinase (MMP-9) antibody (green). Bar is 30 μm .
16
17
18
19
20
21
22
23
24
25

26 **Supplementary Figure 4. Neutrophil granule fractionation and protein content**
27 **separation by electrophoresis**
28
29
30

31 Neutrophil granules were purified as described in Methods and fractionated on a
32 three-layer Percoll gradient, as described previously¹. $\approx 10 \mu\text{g}$ of each sample (α , β 1,
33 β 2 and γ granule fractions) were separated on a 12% SDS-PAGE gel and stained
34 with InstantBlue Protein Stain (Sigma-Aldrich). Indicated bands (a-g) were cut and
35 further analysed by Mass Spectrometry for protein identification (see Supplementary
36 Table 1).
37
38
39
40
41
42
43
44
45
46
47
48

49 **Supplementary Table 1. Fractionated neutrophil granule protein by Mass**
50 **Spectrometry**
51

52 Proteins from gel bands described in Fig. 4 and Supplementary Fig. 4 were further
53 identified by LC-MSMS. The top 3 proteins are herein reported. Proteins selection
54 was done according to 2 criteria: their theoretical mass range must be in accordance
55
56
57
58
59
60
61
62
63
64
65

1
2 with their migration on SDS gel and their iBAQ (Intensity based Absolute
3 Quantification) metrics².
4
5
6

7 **Supplementary Movie01. Dynamics of lactoferrin secretion by neutrophils**
8 **infected with *Shigella flexneri* pGFP, in the presence of RI-MUB₄₀-Cy5.**
9

10 Time-lapse imaging of living purified human neutrophils in the presence of RI-MUB₄₀-
11 Cy5 (magenta, 1 μg/mL) and *S. flexneri* pGFP (MOI 20). Image were acquired every
12 30s using a widefield epifluorescent microscope (Zeiss Definite Focus) at 37°C in the
13 presence of 5% CO₂. Individual images are shown in Fig. 5a.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Supplementary Methods

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Synthesis and cleavage. The synthesis were carried out on a 100 μ moles scale on an ABI 433 synthesizer (Applied Biosystems, Foster City, CA) equipped with a conductivity flow cell to monitor Fmoc deprotection from a polystyrene AM-RAM resin (capacity 0.41 mmol/g for MUB₄₀ peptides and 0.62 mmol/g for retro-inverso RI-MUB₄₀#1, Rapp Polymere GmbH, Tuebingen, Germany). Standard Fmoc amino acids, Dmb, and pseudoproline dipeptides were activated with HCTU (2-(6-Chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylamminium hexafluorophosphate) / DIPEA (N,N-diisopropylethylamine). Fmoc-D-amino acids and Hmb dipeptide were activated with HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo-[4,5-b]pyridinium hexafluorophosphate 3-oxide) / DIPEA). All Fmoc-AAs and surrogates were single-coupled with eight-fold molar excess regarding the resin. Both coupling reagents, N-methyl pyrrolidone (NMP) and standard Fmoc amino acids were obtained from Applied Biosystems. Fmoc D-amino acids were obtained from Eurogentec (Eurogentec, Seraing, Belgium). Fmoc L and D-amino acids were side-protected as follows: tBu for aspartic acid, glutamic acid, serine, threonine, and tyrosine; Trt for cysteine and histidine; Boc for lysine; and Pbf (2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl) for arginine. Fmoc-Asp(OtBu)-(Dmb)Gly-OH dipeptides and pseudoproline (oxazolidine) dipeptides were purchased from Merck-Novabiochem. Fmoc-D-Asp(OtBu)-(Hmb)Gly-OH was purchased from Bachem (Bubendorf, Switzerland). Piperidine was purchased from Sigma-Aldrich (St Louis, MO, USA).

N-terminal acetylation was achieved by treating the peptide resin at the end of the synthesis with acetic anhydride for 30 minutes. As a result, all peptides were N-terminal amide and C-terminal acetylated.

1 Cleavage from the solid support and deprotection of the amino acid side chains were
2 accomplished in one step by 3 h treatment at room temperature with a mixture of
3
4 TFA / ethanedithiol / triisopropylsilane / water (92.5 / 2.5 / 2.5 / 2.5) for MUB₄₀
5
6 peptides or TFA / ethanedithiol / triisopropylsilane / water / phenol (92 / 2.5 / 2 / 2.5
7
8 / 1) for 4 h for RI-MUB₄₀. After filtration of the resin, the cleavage mixtures were
9
10 poured into ice-cold diethyl ether. The precipitates were recovered by centrifugation,
11
12 washed three times with cold diethyl ether, dried, resuspended in a mixture of water
13
14 and acetonitrile, and freeze dried.
15
16
17
18
19

20 *HPLC analysis of synthesized peptides.* Analysis of crude mixtures and purity control
21
22 of the final peptides were performed by RP-HPLC on an Agilent (Santa Clara, CA,
23
24 USA) 1100 Series liquid chromatograph and monitored with a photodiode array
25
26 detector by absorbance at 230 nm, according to the following methods. A linear
27
28 gradient from 15% to 40% of acetonitrile in aqueous solvent A (50mM ammonium
29
30 acetate, pH 6,5) over 20 min was applied at a 0.35 ml/min flow rate on a Symmetry
31
32 300 C18 3.5 μm 2.1 × 100 mm column (Waters, Manchester, UK). To check the
33
34 purity of RI-MUB₄₀ derivatives, supplementary analyses were done in 0.08% aqueous
35
36 TFA by applying a 25%-50% acetonitrile gradient on an Aeris Peptide 3.6μ XB-C18
37
38 column.
39
40
41
42
43

44 *Peptides purification.* The free sulfhydryl crude peptides MUB₄₀#1, #2, & #3 were
45
46 solubilized at a final concentration of 20 mg/ml in a mixture of solvent A and
47
48 acetonitrile, 8:2 v/v. Crude MUB₄₀#4 was solubilized at the same concentration in
49
50 water with aqueous ammoniac (pH8) and 10 equivalent of DTT (1,4-Dithio-DL-
51
52 threitol). Crude RI-MUB₄₀ was solubilized at a final concentration of 3.5 mg/ml in
53
54 solvent A. Those materials were purified by RP-MPLC (AP-100/200 flash, Armen
55
56 Instrument, Saint Ave, France) on a preparative column (26 × 313 mm) packed with
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

100 Å 20 µm C18 Nucleoprep packing (Macherey & Nagel GmbH & Co, Düren, Germany), by applying a linear gradient of 15–70% (MUB₄₀ peptides) or 15-50% (RI-MUB₄₀) solvent B (mixture of acetonitrile and solvent A, 8/2 v/v) in solvent A over 60 min at a 20 ml/min flow rate. The purification was monitored at 214 nm (UV detector K2501, Knauer, Berlin, Germany). The suitable fractions were pooled and freeze dried. The overall isolated yields (from 20% to 30%) were in concordance with the observed synthesis yields deducted from the crude's HPLC analysis.

MUB₄₀ peptides conjugation. Cy5 and Dylight 405 (Thermofisher Scientific) conjugations were operated in a 0.1 M Phosphate buffer pH=6 (MUB₄₀ peptides) or pH=7.2 (RI-MUB₄₀), using 1.2 equivalent of the correspondent maleimide derivative (InvitroGen) in the presence of 1.5 equivalent of TCEP (Tris (2-carboxyethyl)phosphine) per mole of cysteine residue. Repeating one time, this 30 minute coupling protocol was necessary to achieve completion of RI-MUB₄₀ labeling. The labeled peptides were purified by RP-HPLC using a linear gradient of 15–40% acetonitrile over 20 min at a 6 ml/min flow rate, either on a Nucleosil 5µm C18 300 Å semi-preparative column equilibrated in solvent A (MUB₄₀ peptides) or on a Kromasil 5µm C18 300 Å semi-preparative column (AIT, Houilles) equilibrated in 50mM Triethyl ammonium acetate (RI-MUB₄₀). The purity was checked according to the formerly-described HPLC analytical method. The exact concentration was determined by quantitative amino acid analysis (Hitachi, L-8800 analyzer), giving a 50% to 60% conjugation isolated yield.

Biotinylated RI-MUB₄₀ was obtained by adding the free sulfhydryle peptide to 5 equivalents of the maleimide derivative (EZ-linked maleimide-PEG2-biotin, Thermoscience) in 0.1M phosphate buffer (pH6). The biotinylated peptide was purified by HPLC in 50mM ammonium acetate on a Kromasil 5µm C18 300 Å semi-

1 preparative column, using a linear gradient of 15–40% acetonitrile over 20 min at a 6
2 ml/min flow rate. A double peak was observed in the analytical HPLC profile, which
3 was attributed to the resolution of the two isomers resulting from the addition of the
4
5
6
7
8
9

10 *Electrospray ionisation mass spectrometry.* Mass spectrometry was carried out on a
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Electrospray ionisation mass spectrometry. Mass spectrometry was carried out on a quadrupole-TOF Micro mass spectrometer (Waters) equipped with a Z-spray API source. Capillary, sample cone, and extraction cone voltages were set at 3kV, 40V, and 10V, respectively. Source and desolvation temperatures were set at 80 and 250°C, respectively. Data were acquired by scanning over the m/z range 150–2000 at a scan rate of 1 s and an interscan delay of 0.1 s. Peptides were dissolved in a mixture of water/methanol/acetic acid (49.5/49.5/1, v/v/v) at a concentration of 1 µg/µl and analyzed in positive-ion mode by infusion at a flow rate of 5 µl/min. Around fifty spectra were combined and the resultant raw multi-charged spectra were processed using the MaxEnt1 deconvolution algorithm embedded in the Masslynx software. Given the deconvolution process of MaxEnt1, applied to the charged molecules (the Cy5 moiety is positively charged), final characterization was consistent with the expected masses (between brackets) : Cy5-labeled MUB₄₀#1: 5549.740 (5550.115); Cy5-labeled MUB₄₀#2: 5447.472 (5447.933); Cy5-labeled MUB₄₀#3: 5588.273 (5589.170); Cy5-labeled MUB₄₀#4: 5501.778 (5502.093); Cy5-labeled RI-MUB₄₀#1 (RI-MUB₄₀): 5551.265 (5550.115); Dylight 405-labeled MUB₄₀#1 (MUB₄₀-D405): 5519,849 (5518,9.. – restricted proprietary information); RI-MUB₄₀#1-Biotin (RI-MUB₄₀-Biotin): 5296.994 (5296.792).

MUB₄₀ peptides biochemical and biophysical characterization

Size Exclusion Chromatography. Gel filtration was performed using an Agilent 1100

1 system (Agilent Technologies; Palo Alto, CA, USA) and monitored by absorbance at
2 280 nm. MUB₄₀ peptides were solubilized in the gel filtration buffer (20 mM
3 phosphate buffer, 150 mM NaCl, pH7.4) at a concentration of 10µg/ml, 100µg/ml, or
4 1mg/ml), separately injected on a Yarra™ 3µ SEC-2000 300 x 7,8 mm column
5 (Phenomenex, Le Pecq, France), and eluted at a 0,5 ml/min flow rate. The column
6 was calibrated with a mixture of standards proteins (ribonuclease A, 13.7 kDa;
7 carbonic anhydrase 29 kDa; ovalbumin 44kDa; GE Healthcare) complemented with a
8 custom synthetic peptide of our own library (peptide x, 5.1 kDa; Institut Pasteur). The
9 logarithm of the molecular weights were plotted versus the corresponding partition
10 coefficients ($K_{av} = (V_e - V_o)/(V_c - V_o)$; V_e , elution volume; V_o , void volume; V_c ,
11 geometric column volume), giving $\log(M_r) = 2,3108 - 2,2361K_{av}$ as a calibration
12 curve equation.
13

14 *Circular dichroism.* Far-UV Circular Dichroism (CD) spectra were recorded on an
15 Aviv215 spectropolarimeter (Aviv Biomedical) between 190 and 260 nm using a
16 cylindrical cell with a 0.02 cm path length and an averaging time of 1 s per step. Prior
17 analysis, MUB₄₀ peptides were solubilized at a 60 µM final concentration in 20 mM
18 sodium phosphate buffer (pH 7,4) in the presence of 50 mM NaCl. Scans were
19 repeated consecutively three times and merged to produce an averaged spectrum.
20 Results were corrected using buffer baselines measured under the same conditions
21 and normalized to the molar peptide bond concentration and path length as mean
22 molar differential coefficient per residue. MUB₄₀ Peptides were solubilized at a 60 µM
23 final concentration in 20 mM sodium phosphate buffer (pH 7,4) in the presence of 50
24 mM NaCl.
25

26 *Trypsin proteolysis.* MUB₄₀-Cy5 and RI-MUB₄₀-Cy5 were dissolved in 50mM
27 ammonium bicarbonate, pH 8. Prior to digestion and owing to the propensity of
28

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

maleimide derivatives to undergo ring-opening in a basic environment (1), we incubated both peptides at 37°C overnight. Ring-opening completion was checked before trypsin addition. Doing so, we avoided overlapping of N-terminal digest fragments resulting from co-existing succinimidyl thioether and succinamic acid thioether peptides. Along this treatment, minor foot-peaks appeared besides the major peak, which was linked with the well-known side reaction of deamidation and concomitant isomerization, leading to aspartyl and isoaspartyl forms of the peptides (2). Lyophilized trypsin (Thermo scientific) was reconstituted using 50mM acetic acid, diluted with 50mM ammonium bicarbonate and added to the peptide solution so as to obtain a final peptide concentration of 0,25 mg/mL and a protease to protein ratio of 1:20 (w/w). Samples were directly incubated on the injection sampler thermostated at 37°C. HPLC and LC-MS analyses were performed as previously described in Supplementary Information, applying a 15% to 40% linear gradient of acetonitrile in 10mM ammonium acetate over 20 minutes. An Aeris Peptide 3.6µ XB-C18 column was employed for LC-MS analysis of the L-peptide digest fragments, which were identified in positive electrospray ionization mode (data not shown).

Cell biology and neutrophil fractionation

Ethics. All participants gave written informed consent in accordance with the Declaration of Helsinki principles. Peripheral Human blood was collected from healthy patients at the ICAReB service of the Pasteur Institut (authorization DC No.2008-68). Hematopoietic Stem Cells were purified from cytopheresis products collected from healthy patients stimulated 5 days with G-CSF at the Gustave Roussy Cancer Campus (Villejuif, France). Human blood was collected from the antecubital vein into tubes containing sodium citrate (3,8% final) as anticoagulant molecules.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Polymorphonuclear neutrophils purification. Human polymorphonuclear neutrophils were purified as described previously³. Briefly, plasma was removed by centrifugation (450 x g, 15 min); blood cells were resuspended in 0.9% NaCl solution supplemented with 0.72% Dextran. After red blood cells sedimentation, white blood cells were pelleted and further separated on a two layer Percoll (GE Healthcare) (51% - 42%) by centrifugation (at 240 x g, 20 min). PBMC (top layer) were isolated from polymorphonuclear neutrophils (bottom layer). Red blood cells were removed from the latter fraction using CD235a (glycophorin) microbeads (negative selection) (Miltenyi Biotec). PBMCs and polymorphonuclear neutrophils were resuspended in the autologous plasma. Guinea pig and mouse polymorphonuclear neutrophils were purified with the same procedure.

Hematopoietic Stem cells (CD34+) purification, proliferation and differentiation. HSC were purified from cytopheresis products with a CD34 Microbead Kit Ultrapure, according to the manufacturer procedure (Miltenyi). Lin⁻/CD34⁺ HSC purity yield was >98%. CD34⁺ HSC were cultured in StemSpan SFEM II supplemented with SCF (100 ng/ml), IL-3 (10 ng/ml), and IL-6 (100 ng/ml) at 37°C with 5% CO₂. Neutrophil differentiation was induced in StemSpan SFEM II containing G-CSF (10 ng/ml), SCF (100 ng/ml), and IL-3 (10 ng/ml) for 13 days at 37°C with 5% CO₂.

Bacterial strains and growth conditions. *Shigella flexneri* 5a pGFP (M90T) strain was grown in GCTS broth or on TCS agar plates supplemented with 0.01% Congo Red (Sigma-Aldrich) and Ampicillin (100 µg/ml). *Shigella sonnei* was acquired from the Institut Pasteur strain collection (CIP 106347) and is a clinical isolate from a 1999 Paris infection. The strain was grown in GCTS supplemented with Ampicillin (100 µg/ml) to maintain the pMW211 plasmid.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Neutrophil infection. Human purified neutrophils were cultured in glass-bottom dishes (Mattek) for live fluorescent microscopy in a RPMI 1640 (Life Technologies) culture medium supplemented with 10% of heat inactivated Human Serum (Sigma-Aldrich). Neutrophils ($5 \cdot 10^5$ cell/mL in 2 mL) were infected with exponentially-grown *Shigella flexneri* 5a pGFP at a Multiplicity Of Infection (MOI) 20 in RPMI 1640 (Life Technologies) culture medium supplemented with 10 mM HEPES (Life Technologies) at 37°C. Infected neutrophils were centrifuged at 2000 rpm for 10 min prior imaging.

Animal models of shigellosis

Guinea pig. The experimental protocol was approved by the french Ethic Committee Paris (n°20140069, 2014). Young guinea pigs (Hartley, <150g, Charles River) were anaesthetized and infected intrarectally with 10^9 CFU exponentially grown *Shigella flexneri* 5a (M90T) pGFP as previously described^{4 3}. Infection occurred during 8 hours before animals were sacrificed and infected colons collected and fixed in 4% Paraformaldehyde (PFA) for two hours. For immunohistochemical staining, infected guinea pig colon samples were washed in PBS and incubated at 4°C in PBS containing 16% sucrose for 4 hours, followed by incubation in PBS with 30% sucrose overnight. Samples were frozen in OCT (VWR 361603E) on dry ice. Frozen blocks were stored at -80 until sectioning. 10 to 30 μ m sections were obtained using a cryostat CM-3050S (Leica). Tissue slices were labeled in PBS + 0.1% saponin (Sigma-Aldrich) with MUB₄₀-Cy5 or MUB₄₀-Dylight (1 μ g/ml) to localize recruited neutrophils. Slides were washed three times in PBS + 0.1% saponin, three times in PBS, and three times in deionized H₂O and mounted with prolong goldtm mounting media.

Mouse. The experimental protocol was approved by the french Ethic Committee

1 Paris (number 20150042). Female 6 week-old BALB/cJRI mice from Charles River
2 were orally gavaged with streptomycin (100 μ L of 200 mg/ml solution) 24 hours prior
3
4 to *Shigella sonnei* infection. Mice were orally gavaged with 10^{10} CFUs *S. sonnei*
5
6 carrying pMW211 expressing DsRed and monitored for 24 hours. At the end of the
7
8 experiment, animals were sacrificed and tissue sections from the colon were
9
10 extracted. Colon sections were placed in 4% paraformaldehyde (PFA) solution for 2
11
12 hours. PFA fixed tissue sections were passaged for 16 hours in 16% sucrose
13
14 followed by 4 hours in 30% sucrose solutions. Fixed colon slices were embedded in
15
16 OCT (VWR 361603E) and flash frozen in dry ice chilled 2-methylbutane. Frozen
17
18 blocks were stored at -80 until sectioning. A Leica CM3050S cryostat was used to cut
19
20 30 μ M thick colon slices, which were absorbed to glass microscope slides. Tissue
21
22 slices were prepared for fluorescence microscopy by incubation in 0.1% saponin for
23
24 1 hour followed by incubation with fluorescent markers specific for actin (phalloidin-
25
26 FITC, Life Technology) and MUB₄₀-Cy5 at a final 1 μ g/ml concentration. Slides were
27
28 washed in deionized H₂O and mounted with prolong goldtm mounting media.
29
30

31
32
33
34
35
36 *Rabbit.* The experimental protocol was approved by the french Ethic Committee Paris
37
38 1 (number 20070004, December 9th 2007). New Zealand White rabbits weighting
39
40 2.5-3 kg (Charles River) were used for experimental infections. For each animal, up
41
42 to 12 intestinal ligated loops, each 5 cm in length, were prepared as described
43
44 previously⁵⁻⁷ and infected with 10^5 CFU *S. flexneri* pGFP per loop. After 16h, animals
45
46 were sacrificed and collected tissue were fixed in 4% Paraformaldehyde (PFA) for
47
48 two hours. For immunohistochemical staining, infected rabbit ileum samples were
49
50 washed in PBS, incubated at 4°C PBS containing 12% sucrose for 90 min, then in
51
52 PBS with 18% sucrose overnight, and frozen in OCT (Sakura) on dry ice. 7 μ m
53
54 sections were obtained using a cryostat CM-3050 (Leica). Fluorescent staining was
55
56
57
58
59
60
61
62
63
64
65

1 performed in PBS + 0.1% saponin using Phalloidin-RRX (1:1000 dilution) to stain
2 Actin, MUB₄₀-Cy5 (1 μ g/mL) and a mouse anti-lactoferrin primary monoclonal
3 antibody (Hycult biotech, clone 265-1K1, 1:50 dilution) and an anti-mouse-FITC
4 conjugated secondary antibody (1:1000) to stain infiltrated neutrophils. Slides were
5 washed three time in PBS + 0.1% saponin, three times in PBS, and three times in
6 deionized H₂O and mounted with prolong goldtm mounting media.
7
8
9
10
11
12
13
14
15
16

17 **Mass spectrometry analyses**

18
19 *Digestion of proteins.* Coomassie-stained bands detected on gel were cut and rinsed
20 three times in a 50/50 mix of water/acetonitrile (ACN). Proteins were reduced (10 mM
21 Dithiothreitol (DTT)) and further alkylated (50 mM Iodoacetamide) in-gel. In-gel tryptic
22 digestion was performed by adding 400 ng sequencing grade modified trypsin
23 (Promega France, Charbonnières, France) in 50 mM NH₄HCO₃ for 18 h at 37° C.
24 Tryptic peptides were recovered by washing the gel pieces twice in 0.5% FA-50%
25 ACN and once in 100% acetonitrile, and all supernatants were collected in the same
26 tube and evaporated to almost dryness.
27
28
29
30
31
32
33
34
35
36
37

38
39 *LC-MS/MS of tryptic digest.* Digested peptides were analyzed by nano LC-MS/MS
40 using an EASY-nLC 1000 (Thermo Fisher Scientific) coupled to an Orbitrap Q
41 Exactive HF mass spectrometer (Thermo Fisher Scientific, Bremen). Half of each
42 sample was loaded and separated at 250 nl.min⁻¹ on a home-made C₁₈ 30 cm
43 capillary column picotip silica emitter tip (75 μ m diameter filled with 1.9 μ m Reprisil-
44 Pur Basic C₁₈-HD resin, (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany))
45 equilibrated in solvent A (0.1 % FA). Peptides were eluted using a gradient of solvent
46 B (ACN ,0.1 % FA) from 2% to 5% in 5 min, 5% to 35% in 30 min, 30% to 50% in 5
47 min at 250 nL/min flow rate (total length of the chromatographic run was 50 min
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 including high ACN level steps and column regeneration). Mass spectra were
2 acquired in data-dependent acquisition mode with the XCalibur 2.2 software (Thermo
3 Fisher Scientific, Bremen) with automatic switching between MS and MS/MS scans
4 using a top-15 method. MS spectra were acquired at a resolution of 60000 with a
5 target value of 3×10^6 ions. The scan range was limited from 300 to 1700 m/z .
6 Peptide fragmentation was performed via higher-energy collision dissociation (HCD)
7 with the energy set at 28 NCE. Intensity threshold for ions selection was set at $1 \times$
8 10^5 ions with charge exclusion of $z = 1$ and $z > 6$. The MS/MS spectra were acquired
9 at a resolution of 17500 (at m/z 400). Isolation window was set at 2 Th. Dynamic
10 exclusion was employed within 30s.
11

12 Data were searched using MaxQuant¹ (version 1.5.3.8) (with the Andromeda search
13 engine) against a human database (20202 entries, downloaded from Uniprot the
14 2016.05.26).
15

16 The following search parameters were applied: carbamidomethylation of cysteines
17 was set as a fixed modification, and oxidation of methionine and protein N-terminal
18 acetylation were set as variable modifications. The mass tolerances in MS and
19 MS/MS were set to 5 ppm and 20 ppm, respectively. Maximum peptide charge was
20 set to 7, and 5 amino acids were required as minimum peptide length. Results were
21 filtered by a 0.01 false discovery rate at both protein and peptide levels.
22

23 **Microscopy and Image analysis**

24 *Confocal microscopy.* Fixed cells (polymorphonuclear neutrophils, PBMC,
25 haematopoietic stem cells), guinea pig colon and rabbit ileum infected with *S. flexneri*
26 pGFP were imaged on a laser-scanning TCS SP5 confocal microscope (Leica). Z-
27 stack images were taken with 1 μ M step-size increments. Obtained Z-stack images
28
29
30

1 were processed with Fiji software

2 *Spinning disk microscope.* Mouse colons infected with *S. sonnei* pDsRed were
3
4 imaged on a Bruker Opterra fluorescence microscope using a Zeiss Plan-
5
6 Apochromat 63x/1.40 oil immersion lense and Prarie View software version 5.3. Z-
7
8 stack images were taken with 0.5 μ M step-size increments. Obtained Z-stack images
9
10 were stitched with Fiji software version 2.0.0-rc-30/1.49u and visualized using
11
12 IMARIS software version 8.3.1.
13
14

15
16 *Live epifluorescence microscopy.* Viable neutrophils infected with *S. flexneri* pGFP
17
18 were imaged on a Definite focus live microscope (Zeiss) equipped with a temperature
19
20 control chamber (37°C) and a 63x oil immersion objective. Images were acquired
21
22 every 60s. Z-stack images were taken with 2 μ M step-size increments. Obtained Z-
23
24 stack images were processed with Fiji software to generate Movie 01 and the
25
26 corresponding extracted images shown in Fig. 5a.
27
28
29
30

31 *Two-photons microscopy.* Human colonic tissue segments infected with *S. flexneri*
32
33 pGFP were imaged using a commercial laser-scanning microscope (LSM710, Meta,
34
35 Zeiss, Germany) as described previously⁸. MUB₄₀-Cy5 was detected using
36
37 multiphoton excitation (MPE, magenta), Acquisitions were performed with Zen 2008
38
39 SP 1.1 software acquisition package developed by ZEISS. Imaris software
40
41 (<http://www.bitplane.com>) was used to prepare final images.
42
43
44
45
46
47
48
49

50 **Bibliography**


- 51
52 1. Kjeldsen, L., Sengelov, H. & Borregaard, N. Subcellular fractionation of human
53
54 neutrophils on Percoll density gradients. *J. Immunol. Methods* **232**, 131–143
55 (1999).
- 56 2. Schwanhäusser, B. *et al.* Global quantification of mammalian gene expression
57
58 control. *Nature* **473**, 337–342 (2011).
- 59 3. Monceaux, V. *et al.* Anoxia and glucose supplementation preserve neutrophil
60
61 viability and function. *Blood* **128**, 993–1002 (2016).
62
63
64
65

4. Shim, D. H. *et al.* New animal model of shigellosis in the Guinea pig: its usefulness for protective efficacy studies. *J. Immunol.* **178**, 2476–2482 (2007).
5. Jones, S. A. *et al.* Respiration of *Escherichia coli* in the mouse intestine. *Infect. Immun.* **75**, 4891–4899 (2007).
6. Martinez, E., Bartolomé, B. & la Cruz, de, F. pACYC184-derived cloning vectors containing the multiple cloning site and lacZ alpha reporter gene of pUC8/9 and pUC18/19 plasmids. *Gene* **68**, 159–162 (1988).
7. West, N. P. *et al.* Optimization of virulence functions through glucosylation of *Shigella* LPS. *Science* **307**, 1313–1317 (2005).
8. Tyanova, S., Temu, T. & Cox, J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. *Nat Protoc* **11**, 2301–2319 (2016).


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

a


MUB ₄₀ #1	Ac-CTAEGIKKFEG <u>DGY</u> ELFKDNFPAGEKFDND <u>DT</u> NDQFYTVIF-amide
MUB ₄₀ #2	Ac-CGYTDETI <u>PYST</u> AEGIKKFEG <u>DGY</u> ELFKDNFPAGEKFDNDD-amide
MUB ₄₀ #3	Ac-CDQMLRQDDL <u>DGY</u> TDETI <u>PYST</u> AEGIKKFEG <u>DGY</u> ELFKDNF-amide
MUB ₄₀ #4	Ac-CVHVQY <u>IDGE</u> TDQMLRQDDL <u>DGY</u> TDETI <u>PYST</u> AEGIKKFEG-amide

b


A Human Peripheral blood mononuclear cells (PBMCs)



B




C Mouse white blood cells (naïve)




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Rabbit ileal loop infected with *Shigella*



1
2
3 Anderson et al., Fig. S4
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65



	Proteins Identities		Theoretical		Sequence coverage and Number of identified peptide				Identification scores		iBAQ
	Majority protein IDs	Protein Name	Mol. weight	Seq. coverage [%]	# Peptides	# Unique peptides	Q-value	Score			
Band a	sp P02788 TRFL_HUMAN	Lactotransferrin	78,181	88,5	90	86	0	323,31	9312400000		
	sp P05164 PERM_HUMAN	Myeloperoxidase	83,868	37,2	26	23	0	323,31	114180000		
	sp P05107 ITB2_HUMAN	Integrin beta-2	84,781	27,7	16	16	0	323,31	16739000		
	sp P02788 TRFL_HUMAN	Lactotransferrin	78,181	84,4	74	72	0	323,31	3200200000		
Band b	sp P14780 MMP9_HUMAN	Matrix metalloproteinase-9	78,457	29,4	15	15	0	323,31	15290000		
	sp P05164 PERM_HUMAN	Myeloperoxidase	83,868	16,8	11	10	0	323,31	12258000		
	sp P08311 CATG_HUMAN	Cathepsin G	28,837	58,8	23	23	0	278,14	4807900000		
Band c	sp P08246 ELNE_HUMAN	Neutrophil elastase	28,518	46,4	13	13	0	323,31	3319500000		
	sp P24158 PRTN3_HUMAN	Myeloblastin	27,807	44,5	7	7	0	323,31	1497400000		
	sp P80188 NGAL_HUMAN	Neutrophil gelatinase-associated lipocalin	22,588	72,2	16	16	0	323,31	3267000000		
Band d	sp P49913 CAMP_HUMAN	Cathelicidin antimicrobial peptide	19,301	29,4	6	6	0	323,31	122730000		
	sp O75594 PGRP1_HUMAN	Peptidoglycan recognition protein 1	21,731	31,6	4	4	0	323,31	84929000		
	sp P80188 NGAL_HUMAN	Neutrophil gelatinase-associated lipocalin	22,588	72,7	16	16	0	323,31	2875200000		
Band e	sp O75594 PGRP1_HUMAN	Peptidoglycan recognition protein 1	21,731	41,3	5	5	0	323,31	420220000		
	sp Q8X19 MCEM1_HUMAN	Mast cell-expressed membrane protein 1	21,228	17,6	5	5	0	8,1871	32310000		
	sp P49913 CAMP_HUMAN	Cathelicidin antimicrobial peptide	19,301	55,3	11	11	0	323,31	3448600000		
Band f	sp P59666 DEF3_HUMAN;sp P59665 DEF1_HUMAN	Neutrophil defensin 3	10,245	19,1	2	2	0	64,496	624100000		
	sp P61626 LYSC_HUMAN	Lysozyme C	16,537	47,3	5	5	0	323,31	249050000		
	sp P59666 DEF3_HUMAN;sp P59665 DEF1_HUMAN	Neutrophil defensin 3	10,245	26,6	5	5	0	64,496	1423700000		
Band g	sp P06702 S10A9_HUMAN	Protein S100-A9	13,242	56,1	5	5	0	323,31	31961000		
	sp Q9HD89 RETN_HUMAN	Resistin	11,419	21,3	2	2	0	15,809	25285000		

Table S1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65



Click here to access/download

Supplemental Movies and Spreadsheets

AndersonCoic_Movie1.avi

